{"messages":[{"status":"ok","cursor":"1290","count":30,"total":8966}], "collection":[{"rel_doi":"10.1101\/2020.08.12.20156257","rel_title":"Obesity, old age and frailty are the true risk factors for COVID-19 mortality and not chronic disease or ethnicity in Croydon.","rel_date":"2020-08-14","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.12.20156257","rel_abs":"Background: Coronavirus-19 (COVID-19) mortality in hospitalised patients is strongly associated with old age, nursing home residence, male sex and obesity, with a more controversial association with ethnicity and chronic diseases, in particular diabetes mellitus. Further complicating the evaluation of the independent impacts of these risk factors is the failure to control for frailty in the published studies thus far. Aim: To determine the true risk factors for mortality in patients confirmed to have COVID-19 in Croydon needing hospital admission and to evaluate the independence of these risk factors in this group after adjusting for body mass index (BMI) and frailty. Methods: This observational study retrospectively reviewed hospital electronic medical records of 466 consecutive patients who were admitted to Croydon University Hospital confirmed positive by rapid PCR test from 11th March 2020 to 9th April 2020. Statistical analysis was performed by multiple unconditional and univariate logistic regression. Results: After multivariate analysis, male sex [OR 1.44 (CI 0.92-2.40)], age (per year) [OR 1.07 (CI 1.05-1.09)], morbid obesity (BMI > 40 kg\/m2 vs reference BMI 18.5-24.9 kg\/m2 ) [OR 14.8 (CI 5.25-41.8)], and nursing home residence (OR 3.01 (CI 1.56-5.79) were independently associated with COVID-19 mortality with no statistically significant association found with chronic diseases or ethnicity. In the non-nursing home population, after adjusting for age and sex, the odds ratio for type 2 diabetes mellitus (T2DM) as a risk factor was 1.64 (CI 1.03-2.61, p = 0.03) and was and was attenuated to 1.30 (CI 0.78-2.18)) after controlling for BMI; the association of mortality with male sex was strengthened [OR 1.66 (CI 0.96-2.87)] and that for ethnic minority patients was weakened [South Asians [from OR 1.30 (CI 0.67-2.53)) to OR 1.21 (CI 0.60-2.46)]; African Caribbeans [from OR 1.24 (CI 0.65-2.34) to OR 1.16 (CI 0.58-2.30)]. There was a borderline but potentially large protective effect (p= 0.09) in patients who were on anticoagulation drugs prior to admission [OR 0.56 (CI 0.28-1.11)]. Conclusion: Our study found no significant effect of ethnicity and chronic diseases as independent risk factors on COVID-19 mortality in Croydon population whereas male sex, high BMI, old age and frailty were found to be independent risk factors. Routine prophylactic treatment with anticoagulant drugs in the high-risk COVID-19 population warrants further prompt investigation.","rel_num_authors":5,"rel_authors":[{"author_name":"Zinu Philipose","author_inst":"Croydon University Hospital"},{"author_name":"Nadia Smati","author_inst":"Croydon University Hospital"},{"author_name":"Chun Shing Jefferson Wong","author_inst":"Croydon University Hospital"},{"author_name":"Karen Aspey","author_inst":"Croydon University Hospital"},{"author_name":"Michael Anthony Mendall","author_inst":"Croydon University Hospital"}],"version":"1","license":"cc_by_nc_nd","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.08.12.20173252","rel_title":"Integrating psychosocial variables and societal diversity in epidemic models for predicting COVID-19 transmission dynamics","rel_date":"2020-08-14","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.12.20173252","rel_abs":"During the current COVID-19 pandemic, governments must make decisions based on a variety of information including estimations of infection spread, health care capacity, economic and psychosocial considerations. The disparate validity of current short-term forecasts of these factors is a major challenge to governments. By causally linking an established epidemiological spread model with dynamically evolving psychosocial variables, using Bayesian inference we estimate the strength and direction of these interactions for German and Danish data of disease spread, human mobility, and psychosocial factors based on the serial cross-sectional COVID-19 Snapshot Monitoring (COSMO; N = 16,981). We demonstrate that the strength of cumulative influence of psychosocial variables on infection rates is of a similar magnitude as the influence of physical distancing. We further show that the efficacy of political interventions to contain the disease strongly depends on societal diversity, in particular group-specific sensitivity to affective risk perception. As a consequence, the model may assist in quantifying the effect and timing of interventions, forecasting future scenarios, and differentiating the impact on diverse groups as a function of their societal organization. Importantly, the careful handling of societal factors, including support to the more vulnerable groups, adds another direct instrument to the battery of political interventions fighting epidemic spread.","rel_num_authors":13,"rel_authors":[{"author_name":"Viktor Jirsa","author_inst":"Aix-Marseille University"},{"author_name":"Spase Petkoski","author_inst":"Aix-Marseille University"},{"author_name":"Huifang Wang","author_inst":"Aix-Marseille University"},{"author_name":"Marmaduke Woodman","author_inst":"Aix-Marseille University"},{"author_name":"Jan Fousek","author_inst":"Aix-Marseille University"},{"author_name":"Cornelia Betsch","author_inst":"Erfurt University"},{"author_name":"Lisa Felgendreff","author_inst":"Erfurt University"},{"author_name":"Robert Bohm","author_inst":"Copenhagen University"},{"author_name":"Lau Lilleholt","author_inst":"Copenhagen University"},{"author_name":"Ingo Zettler","author_inst":"Copenhagen University"},{"author_name":"Sarah Faber","author_inst":"Baycrest Research Center"},{"author_name":"Kelly Shen","author_inst":"Baycrest Research Center"},{"author_name":"Anthony Randal McIntosh","author_inst":"Baycrest Research Center"}],"version":"1","license":"cc_by_nc_nd","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.08.12.20173609","rel_title":"Frontline healthcare workers' knowledge and perception of COVID-19 and willingness to work during the pandemic in Nepal: a nationwide cross-sectional web-based study","rel_date":"2020-08-14","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.12.20173609","rel_abs":"Abstract Background The health sector's effectiveness during a pandemic primarily depends on the availability, knowledge, skills, perceptions, and motivations of frontline healthcare workers. In this study, we aimed to investigate the contextual factors associated with the knowledge, perceptions, and the willingness of frontline healthcare workers to work during the COVID-19 pandemic in Nepal. Methods A total of 1051 frontline health-workers from all seven Nepalese provinces were included in this web-based cross-sectional study, which was conducted in May 2020. Using a 5-point Likert scale questionnaire, we collected information on knowledge, perceptions, and the willingness of frontline healthcare workers to work during the COVID-19 pandemic. Multivariable logistic regression was applied to identify independent associations between predictors and outcome variables. Results Of the 1051 frontline health-workers, 17.2% were found to have inadequate knowledge on COVID-19, 63.6% reported unsatisfactory perceptions of government response, and 35.9% showed an unwillingness to work during the pandemic. Health workers at local health facilities (AOR: 0.35; 95% CI: 0.17-0.68) and those with chronic diseases were less likely to have adequate knowledge of COVID-19. Nurses (AOR: 2.10; 95% CI: 1.38-3.18), health-workers from Karnali Province (AOR: 2.62; 95% CI: 1.52-4.53), and those who had adequate knowledge of COVID-19 (AOR: 3.86; 95% CI: 2.51-6.16) were more likely to have satisfactory perception towards government response to COVID-19. In addition, laboratory-workers, health workers from Karnali province, and those with adequate knowledge (AOR: 1.81; 95% CI: 1.27-2.58) were more likely to work during the COVID-19 pandemic. Conclusions We concluded that frontline healthcare workers have some gaps in knowledge-related to COVID-19; about two-thirds of them had a negative perception of government response, and nearly one-third of them were unwilling to work. These observations demonstrate that prompt actions are required to improve health-worker knowledge of COVID-19, address negative perceptions to government responses, and motivate them to provide healthcare services during the pandemic. Keywords: COVID-19, Health-workers, Knowledge, Perception, Willingness","rel_num_authors":19,"rel_authors":[{"author_name":"DIPAK PRASAD UPADHYAYA","author_inst":"Central Department of Public Health, Institute of Medicine, Tribhuvan University, Kathmandu, Nepal"},{"author_name":"Rajan Paudel","author_inst":"Central Department of Public Health, Institute of Medicine, Tribhuvan University, Kathmandu, Nepal"},{"author_name":"Daniel J Bromberg","author_inst":"Department of Social and Behavioral Sciences, Yale School of Public Health, Yale University, New Haven, CT, USA"},{"author_name":"Dilaram Acharya","author_inst":"Department of Preventive Medicine, College of Medicine, Dongguk University, South Korea"},{"author_name":"Kaveh Khoshnood","author_inst":"Department of Epidemiology of Microbial Diseases, Yale School of Public Health, Yale University, New Haven CT, USA"},{"author_name":"Kwan Lee","author_inst":"Department of Preventive Medicine, College of Medicine, Dongguk University, Gyeongju 38066 South Korea"},{"author_name":"Ji-Huyuk Park","author_inst":"Department of Preventive Medicine, College of Medicine, Dongguk University, South Korea"},{"author_name":"Seok-Ju Yoo","author_inst":"Department of Preventive Medicine, College of Medicine, Dongguk University, South Korea"},{"author_name":"Archana Shrestha","author_inst":"Department of Public Health, Kathmandu University, Kathmandu, Nepal"},{"author_name":"Bom BC","author_inst":"Ministry of Health and Population, Kathmandu, Nepal"},{"author_name":"Sabin Bhandari","author_inst":"B.P Koirala Institute of Health Sciences, Dharan, Nepal"},{"author_name":"Ramgyan Yadav","author_inst":"Ministry of Health and Population, Kathmandu, Nepal"},{"author_name":"Ashish Timalsina","author_inst":"Ministry of Health and Population, Kathmandu, Nepal"},{"author_name":"Chetan Nidhi Wagle","author_inst":"Ministry of Health and Population, Kathmandu, Nepal"},{"author_name":"Brij Kumar Das","author_inst":"Ministry of Health and Population, Kathmandu, Nepal"},{"author_name":"Ramesh Kunwar","author_inst":"Ministry of Health and Population, Kathmandu, Nepal"},{"author_name":"Binaya Chalise","author_inst":"Hiroshima University, Graduate School for International Development and Cooperation, Hiroshima, Japan"},{"author_name":"Deepak Raj Bhatta","author_inst":"Ministry of Health and Population, Kathmandu, Nepal"},{"author_name":"Mukesh Adhikari","author_inst":"Department of Health Policy and Management, Yale School of Public Health, Yale University, New Haven CT, USA"}],"version":"1","license":"cc_by","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.08.12.20173856","rel_title":"Comparative Evaluation of SARS-CoV-2 IgG Assays in India","rel_date":"2020-08-14","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.12.20173856","rel_abs":"IgG immunoassays have been developed and used widely for clinical samples and serosurveys for SARS-CoV-2. We compared the performance of three immunoassays, an in-house RBD assay, and two commercial assays, the Diasorin LIAISON SARS-CoV-2 IgG CLIA which detects antibodies against S1\/S2 domains of the Spike protein and the Zydus Kavach assay based on inactivated virus using a well-characterized sera-panel. 379 sera\/plasma samples from RT-PCR positive individuals >20 days of illness in symptomatic or RT-PCR positivity in asymptomatic individuals and 184 pre-pandemic samples were used. The sensitivity of the assays were 84.7, 82.6 and 75.7 respectively for RBD, LIAISON and Kavach. Kavach and the in-house RBD ELISA showed a specificity of 99.5% and 100%, respectively. The RBD and LIAISON (S1\/S2) assays showed high agreement (94.7%;95%CI:92.0,96.6) and were able to correctly identify more positives than Kavach. All three assays are suitable for serosurveillance studies, but in low prevalence sites, estimation of exposure may require adjustment based on our findings.","rel_num_authors":2,"rel_authors":[{"author_name":"- DBT India Consortium for Covid-19 Research","author_inst":""},{"author_name":"Shinjini Bhatnagar","author_inst":"Translational Health Science and Technology Institute"},{"author_name":"Daniel J Bromberg","author_inst":"Department of Social and Behavioral Sciences, Yale School of Public Health, Yale University, New Haven, CT, USA"},{"author_name":"Dilaram Acharya","author_inst":"Department of Preventive Medicine, College of Medicine, Dongguk University, South Korea"},{"author_name":"Kaveh Khoshnood","author_inst":"Department of Epidemiology of Microbial Diseases, Yale School of Public Health, Yale University, New Haven CT, USA"},{"author_name":"Kwan Lee","author_inst":"Department of Preventive Medicine, College of Medicine, Dongguk University, Gyeongju 38066 South Korea"},{"author_name":"Ji-Huyuk Park","author_inst":"Department of Preventive Medicine, College of Medicine, Dongguk University, South Korea"},{"author_name":"Seok-Ju Yoo","author_inst":"Department of Preventive Medicine, College of Medicine, Dongguk University, South Korea"},{"author_name":"Archana Shrestha","author_inst":"Department of Public Health, Kathmandu University, Kathmandu, Nepal"},{"author_name":"Bom BC","author_inst":"Ministry of Health and Population, Kathmandu, Nepal"},{"author_name":"Sabin Bhandari","author_inst":"B.P Koirala Institute of Health Sciences, Dharan, Nepal"},{"author_name":"Ramgyan Yadav","author_inst":"Ministry of Health and Population, Kathmandu, Nepal"},{"author_name":"Ashish Timalsina","author_inst":"Ministry of Health and Population, Kathmandu, Nepal"},{"author_name":"Chetan Nidhi Wagle","author_inst":"Ministry of Health and Population, Kathmandu, Nepal"},{"author_name":"Brij Kumar Das","author_inst":"Ministry of Health and Population, Kathmandu, Nepal"},{"author_name":"Ramesh Kunwar","author_inst":"Ministry of Health and Population, Kathmandu, Nepal"},{"author_name":"Binaya Chalise","author_inst":"Hiroshima University, Graduate School for International Development and Cooperation, Hiroshima, Japan"},{"author_name":"Deepak Raj Bhatta","author_inst":"Ministry of Health and Population, Kathmandu, Nepal"},{"author_name":"Mukesh Adhikari","author_inst":"Department of Health Policy and Management, Yale School of Public Health, Yale University, New Haven CT, USA"}],"version":"1","license":"cc_no","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.08.13.20173757","rel_title":"LAMP-BEAC: Detection of SARS-CoV-2 RNA Using RT-LAMP and Molecular Beacons","rel_date":"2020-08-14","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.13.20173757","rel_abs":"SARS-CoV-2 has caused a global pandemic, resulting in the need for rapid assays to allow diagnosis and prevention of transmission. Reverse Transcription-Polymerase Chain Reaction (RT-PCR) provides a gold standard assay for SARS-CoV-2 RNA, but tests are expensive and supply chains are potentially fragile, motivating interest in additional assay methods. Reverse transcription and Loop Mediated Isothermal Amplification (RT-LAMP) provides an alternative that uses alternative and often cheaper reagents without the need for thermocyclers. The presence of SARS-CoV-2 RNA is typically detected using dyes to report bulk amplification of DNA; however a common artifact is nonspecific DNA amplification, complicating detection. Here we describe the design and testing of molecular beacons, which allow sequence-specific detection of SARS-CoV-2 genomes with improved discrimination in simple reaction mixtures. We also show how beacons with different fluorescent labels can allow convenient multiplex detection of several amplicons in \"single pot\" reactions.","rel_num_authors":10,"rel_authors":[{"author_name":"Scott Sherrill-Mix","author_inst":"Perelman School of Medicine, University of Pennsylvania"},{"author_name":"Young Hwang","author_inst":"Perelman School of Medicine, University of Pennsylvania"},{"author_name":"Aoife M Roche","author_inst":"Perelman School of Medicine, University of Pennsylvania"},{"author_name":"Susan R Weiss","author_inst":"Perelman School of Medicine, University of Pennsylvania"},{"author_name":"Yize Li","author_inst":"Perelman School of Medicine, University of Pennsylvania"},{"author_name":"Jevon Graham-Wooten","author_inst":"Perelman School of Medicine, University of Pennsylvania"},{"author_name":"Louis J Taylor","author_inst":"Perelman School of Medicine, University of Pennsylvania"},{"author_name":"Ronald G Collman","author_inst":"Perelman School of Medicine, University of Pennsylvania"},{"author_name":"Gregory D Van Duyne","author_inst":"Perelman School of Medicine, University of Pennsylvania"},{"author_name":"Frederic D Bushman","author_inst":"Perelman School of Medicine, University of Pennsylvania"},{"author_name":"Sabin Bhandari","author_inst":"B.P Koirala Institute of Health Sciences, Dharan, Nepal"},{"author_name":"Ramgyan Yadav","author_inst":"Ministry of Health and Population, Kathmandu, Nepal"},{"author_name":"Ashish Timalsina","author_inst":"Ministry of Health and Population, Kathmandu, Nepal"},{"author_name":"Chetan Nidhi Wagle","author_inst":"Ministry of Health and Population, Kathmandu, Nepal"},{"author_name":"Brij Kumar Das","author_inst":"Ministry of Health and Population, Kathmandu, Nepal"},{"author_name":"Ramesh Kunwar","author_inst":"Ministry of Health and Population, Kathmandu, Nepal"},{"author_name":"Binaya Chalise","author_inst":"Hiroshima University, Graduate School for International Development and Cooperation, Hiroshima, Japan"},{"author_name":"Deepak Raj Bhatta","author_inst":"Ministry of Health and Population, Kathmandu, Nepal"},{"author_name":"Mukesh Adhikari","author_inst":"Department of Health Policy and Management, Yale School of Public Health, Yale University, New Haven CT, USA"}],"version":"1","license":"cc_by_nc","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.08.13.20173807","rel_title":"Validation of Saliva and Self-Administered Nasal Swabs for COVID-19 Testing","rel_date":"2020-08-14","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.13.20173807","rel_abs":"Background Active cases of COVID-19 has primarily been diagnosed via RT-PCR of nasopharyngeal (NP) swabs. Saliva and self-administered nasal (SN) swabs can be collected safely without trained staff. We aimed to test the sensitivity of naso-oropharyngeal saliva and SN swabs compared to NP swabs in a large cohort of migrant workers in Singapore. Methods We recruited 200 male adult subjects: 45 with acute respiratory infection, 104 asymptomatic close contacts, and 51 confirmed COVID-19 cases. Each subject underwent NP swab, SN swab and saliva collection for RT-PCR testing at 1 to 3 timepoints. We additionally used a direct-from-sample amplicon-based next-generation sequencing (NGS) workflow to establish phylogeny. Results Of 200 subjects, 91 and 46 completed second and third rounds of testing, respectively. Of 337 sets of tests, there were 150 (44.5%) positive NP swabs, 127 (37.7%) positive SN swabs, and 209 (62.0%) positive saliva. Test concordance between different sample sites was good, with a kappa statistic of 0.616 for NP and SN swabs, and 0.537 for NP and saliva. In confirmed symptomatic COVID-19 subjects, the likelihood of a positive test from any sample fell beyond 14 days of symptom onset. NGS was conducted on 18 SN and saliva samples, with phylogenetic analyses demonstrating lineages for all samples tested were Clade O (GISAID nomenclature) and lineage B.6 (PANGOLIN nomenclature). Conclusion This study supports saliva as a sensitive and less intrusive sample for COVID-19 diagnosis and further delineates the role of oropharyngeal secretions in increasing the sensitivity of testing. However, SN swabs were inferior as an alternate sample type. Our study also provides evidence that a straightforward next-generation sequencing workflow can provide direct-from-sample phylogenetic analysis for public health decision-making.","rel_num_authors":11,"rel_authors":[{"author_name":"Alvin Kuo Jing Teo","author_inst":"Saw Swee Hock School of Public Health"},{"author_name":"Yukti Choudhury","author_inst":"Lucence Diagnostics"},{"author_name":"Iain Beehuat Tan","author_inst":"National Cancer Centre, Singapore"},{"author_name":"Chae Yin Cher","author_inst":"Lucence Diagnostics"},{"author_name":"Shi Hao Chew","author_inst":"Singapore Armed Forces"},{"author_name":"Zi Yi Wan","author_inst":"Lucence Diagnostics"},{"author_name":"Lionel Tim Ee Cheng","author_inst":"Singapore General Hospital"},{"author_name":"Lynette Lin Ean Oon","author_inst":"Singapore General Hospital"},{"author_name":"Min Han Tan","author_inst":"Lucence Diagnostics"},{"author_name":"Kian Sing Chan","author_inst":"Singapore General Hospital"},{"author_name":"Li Yang Hsu","author_inst":"Saw Swee Hock School of Public Health"},{"author_name":"Ramgyan Yadav","author_inst":"Ministry of Health and Population, Kathmandu, Nepal"},{"author_name":"Ashish Timalsina","author_inst":"Ministry of Health and Population, Kathmandu, Nepal"},{"author_name":"Chetan Nidhi Wagle","author_inst":"Ministry of Health and Population, Kathmandu, Nepal"},{"author_name":"Brij Kumar Das","author_inst":"Ministry of Health and Population, Kathmandu, Nepal"},{"author_name":"Ramesh Kunwar","author_inst":"Ministry of Health and Population, Kathmandu, Nepal"},{"author_name":"Binaya Chalise","author_inst":"Hiroshima University, Graduate School for International Development and Cooperation, Hiroshima, Japan"},{"author_name":"Deepak Raj Bhatta","author_inst":"Ministry of Health and Population, Kathmandu, Nepal"},{"author_name":"Mukesh Adhikari","author_inst":"Department of Health Policy and Management, Yale School of Public Health, Yale University, New Haven CT, USA"}],"version":"1","license":"cc_by_nd","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.08.12.20170282","rel_title":"Observational Study on Clinical Features, Treatment and Outcome of COVID 19 in a tertiary care Centre in India- a retrospective case series","rel_date":"2020-08-14","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.12.20170282","rel_abs":"ABSTRACT Objective: This study will attempt to explore the demographic profile and outcome in the patients receiving multidisciplinary, personalised approach including use of Broad Spectrum Antivirals - Ivermectin, anti-inflammatory and antioxidants roles of Statins and N-acetyl-cysteine along with Standard of Care (SOC) in hospitalised COVID19 patients in a tertiary care centre. Setting: Inpatient department Participants: 191 COVID-19 patients with laboratory confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in the year 2020 between June 14- 28, 2020 Main outcome measures: The outcome of Interests are : Studying the demographic profile of COVID 19 cases Study the treatment outcomes in terms of death or discharge in patients receiving Ivermectin+N-acetyl-cysteine+Statin along with Standard of care. Results: 148 patients were included in the study. All of them had confirmed COVID19 infection by the rtPCR method. Average age of the patients was 57.57 years ( Range = 17 - 88), 49% were male, 51% female. 81% of the patients had at least one or more comorbidities. Most common comorbidities included diabetes( 32%), Hypertension (27%),Ischaemic Heart Disease (8%). More comorbidities. The in hospital, Case Fatality Rate was therefore, 1.35 %. The remaining 144 were discharged from the facility after an average 12 days duration of stay. Conclusions: Triple therapy with ivermectin + atorvastatin + N-acetylcysteine can be an useful adjunct to standard of care. Keywords: SARS-CoV-2, COVID-19, outpatients, treatment, zinc, hydroxychloroquine, azithromycin","rel_num_authors":6,"rel_authors":[{"author_name":"Raja Bhattacharya","author_inst":"Medical College, Kolkata"},{"author_name":"Rohini Ghosh","author_inst":"Medical College, Kolkata"},{"author_name":"Manish Kulshrestha","author_inst":"Medical College, Kolkata"},{"author_name":"Sampurna Chowdhury","author_inst":"Medical College Kolkata"},{"author_name":"Rishav Mukherjee","author_inst":"Medical College, Kolkata"},{"author_name":"Indranil Ray","author_inst":"Medical College, Kolkata"},{"author_name":"Lionel Tim Ee Cheng","author_inst":"Singapore General Hospital"},{"author_name":"Lynette Lin Ean Oon","author_inst":"Singapore General Hospital"},{"author_name":"Min Han Tan","author_inst":"Lucence Diagnostics"},{"author_name":"Kian Sing Chan","author_inst":"Singapore General Hospital"},{"author_name":"Li Yang Hsu","author_inst":"Saw Swee Hock School of Public Health"},{"author_name":"Ramgyan Yadav","author_inst":"Ministry of Health and Population, Kathmandu, Nepal"},{"author_name":"Ashish Timalsina","author_inst":"Ministry of Health and Population, Kathmandu, Nepal"},{"author_name":"Chetan Nidhi Wagle","author_inst":"Ministry of Health and Population, Kathmandu, Nepal"},{"author_name":"Brij Kumar Das","author_inst":"Ministry of Health and Population, Kathmandu, Nepal"},{"author_name":"Ramesh Kunwar","author_inst":"Ministry of Health and Population, Kathmandu, Nepal"},{"author_name":"Binaya Chalise","author_inst":"Hiroshima University, Graduate School for International Development and Cooperation, Hiroshima, Japan"},{"author_name":"Deepak Raj Bhatta","author_inst":"Ministry of Health and Population, Kathmandu, Nepal"},{"author_name":"Mukesh Adhikari","author_inst":"Department of Health Policy and Management, Yale School of Public Health, Yale University, New Haven CT, USA"}],"version":"1","license":"cc_no","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.08.10.20170761","rel_title":"Clinical and immunological factors that distinguish COVID-19 from pandemic influenza A(H1N1)","rel_date":"2020-08-14","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.10.20170761","rel_abs":"The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), is a global health threat with the potential to cause severe disease manifestations in the lungs. Although clinical descriptions of COVID-19 are currently available, the factors distinguishing SARS-CoV-2 from other respiratory viruses are unknown. Here, we compared the clinical, histopathological, and immunological characteristics of patients with COVID-19 and pandemic influenza A(H1N1). We observed a higher frequency of respiratory symptoms, increased tissue injury markers, a histological pattern of alveolar pneumonia, and higher levels of IL-1RA, TNF-, CCL3, G-CSF, APRIL, sTNF-R1, sTNF-R2, sCD30, and sCD163 in influenza patients. Conversely, dry cough, gastrointestinal symptoms, interstitial lung pathology, increased Th1 (IL-12, IFN-{gamma}) and Th2 (IL-4, IL-5, IL-10, IL-13) cytokine levels, along with IL-1{beta}, IL-6, CCL11, VEGF, TWEAK, TSLP, MMP-1, and MMP-3, were observed in COVID-19 cases. We demonstrated the diagnostic potential of some clinical and immune factors to differentiate COVID-19 from pandemic influenza A(H1N1). Our data suggest that SARS-CoV-2 induces a dysbalanced polyfunctional inflammatory response that is different from the immune response against influenza. These findings might be relevant for the upcoming 2020-2021 influenza season, which is projected to be historically unique due to its convergence with COVID-19.","rel_num_authors":38,"rel_authors":[{"author_name":"Jose Alberto Choreno-Parra","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Luis Armando Jimenez-Alvarez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Alfredo Cruz Lagunas","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Tatiana Sofia Rodriguez-Reyna","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Gustavo Ramirez-Martinez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico."},{"author_name":"Montserrat Sandoval-Vega","author_inst":"Facultad de Estudios Superiores Iztacala, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico"},{"author_name":"Diana Lizeth Hernandez-Garcia","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico."},{"author_name":"Eduardo M. Choreno-Parra","author_inst":"Posgrado en Ciencias Biologicas, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico"},{"author_name":"Yalbi I. Balderas-Martinez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Mariana Esther Martinez-Sanchez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Eduardo Marquez-Garcia","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Edda Sciutto","author_inst":"Instituto de Investigaciones Biomedicas, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico"},{"author_name":"Jose Moreno-Rodriguez","author_inst":"Hospital Juarez de Mexico, Mexico City, Mexico"},{"author_name":"Jose Omar Barreto-Rodriguez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Hazel Vazquez-Rojas","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Gustavo Ivan Centeno-Saenz","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael CosIo Villegas (INER), Mexico City, Mexico"},{"author_name":"Nestor Alvarado-Pena","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Citlaltepetl Salinas-Lara","author_inst":"Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez (INNyN), Mexico City, Mexico"},{"author_name":"Carlos Sanchez-Garibay","author_inst":"Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez (INNyN), Mexico City, Mexico"},{"author_name":"Gabriela Hernandez-Molina","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Criselda Mendoza-Milla","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Andrea Dominguez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Julio Granados","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Lula Mena-Hernandez","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Luis Angel Perez-Buenfil","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Guillermo Dominguez-Cheritt","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Carlos Cabello-Gutierrez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Cesar Luna-Rivero","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Jorge Salas-Hernandez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Patricio Santilla-Doherty","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Justino Regalado","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Angelica Hernandez-Martinez","author_inst":"Instituto Nacional de Medicina Genomica, Mexico City, Mexico"},{"author_name":"Lorena Orozco","author_inst":"Instituto Nacional de Medicina Genomica, Mexico City, Mexico"},{"author_name":"Ethel A. Garcia-Latorre","author_inst":"Escuela Nacional de Ciencias Biologicas, Instituto Politecnico Nacional, Mexico City, Mexico"},{"author_name":"Carmen M. Hernandez-Cardenas","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Shabaana A. Khader","author_inst":"Department of Molecular Microbiology, Washington University School of Medicine in St Louis, MO, United States"},{"author_name":"Albert Zlotnik","author_inst":"Department of Physiology & Biophysics School of Medicine, Institute for Immunology, University of California, Irvine, United-States"},{"author_name":"Joaquin Zuniga","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"}],"version":"1","license":"cc_no","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.08.12.20166579","rel_title":"COVID-19 Severity Index: predictive score for hospitalized patients","rel_date":"2020-08-14","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.12.20166579","rel_abs":"Introduction: Pandemics pose a major challenge for public health preparedness, requiring a coordinated international response and the development of solid containment plans. An early and accurate identification of high-risk patients in the course of the actual COVID-19 pandemic is vital for planning and for making proper use of available resources. Objective: The purpose of this study was to identify the key variables to create a predictive model that could be used effectively for triage. Method: A narrative literature review of 651 articles was conducted to assess clinical, laboratory and imaging findings of COVID-19 confirmed cases. After screening, 10 articles met the inclusion criteria and a list of suggested variables was gathered. A modified Delphi process analysis was performed to consult experts in order to generate a final list of variables for the creation of the predictive model. Results: The modified Delphi process analysis identified 44 predictive variables that were used for building a severity prediction score, the COVID-19 Severity Index. Conclusion: Specifically designed for current COVID-19 pandemic, COVID-19 Severity Index could be used as a reliable tool for strategic planning, organization and administration of resources by easily identifying hospitalized patients with higher risk of transfer to Intensive Care Unit (ICU).","rel_num_authors":10,"rel_authors":[{"author_name":"Ivan Huespe","author_inst":"Intensive Care Unit, Hospital Italiano de Buenos Aires"},{"author_name":"Indalecio Carboni Bisso","author_inst":"Intensive Care Unit, Hospital Italiano de Buenos Aires"},{"author_name":"Nicolas Alejandro Gemelli","author_inst":"Intensive Care Unit, Hospital Italiano de Buenos Aires"},{"author_name":"Sergio Adrian Terrasa","author_inst":"Research Department, Hospital Italiano de Buenos Aires"},{"author_name":"Sabrina Di Stefano","author_inst":"Intensive Care Unit, Hospital Italiano de Buenos Aires"},{"author_name":"Valeria Burgos","author_inst":"Institute of translational medicine and biomedical engineering, Hospital Italiano de Buenos Aires, IUHI, CONICET"},{"author_name":"Jorge Federico Sinner","author_inst":"Intensive Care Unit, Hospital Italiano de Buenos Aires"},{"author_name":"Marcelo Raul Risk","author_inst":"Institute of translational medicine and biomedical engineering, Hospital Italiano de Buenos Aires, IUHI, CONICET"},{"author_name":"Eduardo San Roman","author_inst":"Intensive Care Unit, Hospital Italiano de Buenos Aires"},{"author_name":"Marcos Jose Las Heras","author_inst":"Intensive Care Unit, Hospital Italiano de Buenos Aires"},{"author_name":"Eduardo Marquez-Garcia","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Edda Sciutto","author_inst":"Instituto de Investigaciones Biomedicas, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico"},{"author_name":"Jose Moreno-Rodriguez","author_inst":"Hospital Juarez de Mexico, Mexico City, Mexico"},{"author_name":"Jose Omar Barreto-Rodriguez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Hazel Vazquez-Rojas","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Gustavo Ivan Centeno-Saenz","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael CosIo Villegas (INER), Mexico City, Mexico"},{"author_name":"Nestor Alvarado-Pena","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Citlaltepetl Salinas-Lara","author_inst":"Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez (INNyN), Mexico City, Mexico"},{"author_name":"Carlos Sanchez-Garibay","author_inst":"Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez (INNyN), Mexico City, Mexico"},{"author_name":"Gabriela Hernandez-Molina","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Criselda Mendoza-Milla","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Andrea Dominguez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Julio Granados","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Lula Mena-Hernandez","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Luis Angel Perez-Buenfil","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Guillermo Dominguez-Cheritt","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Carlos Cabello-Gutierrez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Cesar Luna-Rivero","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Jorge Salas-Hernandez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Patricio Santilla-Doherty","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Justino Regalado","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Angelica Hernandez-Martinez","author_inst":"Instituto Nacional de Medicina Genomica, Mexico City, Mexico"},{"author_name":"Lorena Orozco","author_inst":"Instituto Nacional de Medicina Genomica, Mexico City, Mexico"},{"author_name":"Ethel A. Garcia-Latorre","author_inst":"Escuela Nacional de Ciencias Biologicas, Instituto Politecnico Nacional, Mexico City, Mexico"},{"author_name":"Carmen M. Hernandez-Cardenas","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Shabaana A. Khader","author_inst":"Department of Molecular Microbiology, Washington University School of Medicine in St Louis, MO, United States"},{"author_name":"Albert Zlotnik","author_inst":"Department of Physiology & Biophysics School of Medicine, Institute for Immunology, University of California, Irvine, United-States"},{"author_name":"Joaquin Zuniga","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"}],"version":"1","license":"cc_by_nc","type":"PUBLISHAHEADOFPRINT","category":"intensive care and critical care medicine"},{"rel_doi":"10.1101\/2020.08.11.20172734","rel_title":"Social Network Analysis of COVID-19 Transmission in Karnataka, India","rel_date":"2020-08-14","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.11.20172734","rel_abs":"We used social network analysis (SNA) to study the novel coronavirus (COVID-19) outbreak in Karnataka, India, and assess the potential of SNA as a tool for outbreak monitoring and control. We analyzed contact tracing data of 1147 Covid-19 positive cases (mean age 34.91 years, 61.99% aged 11-40, 742 males), anonymized and made public by the government. We used software tools Cytoscape and Gephi to create SNA graphics and determine network attributes of nodes (cases) and edges (directed links, determined by contact tracing, from source to target patients). Outdegree was 1-47 for 199 (17.35%) nodes, and betweenness 0.5-87 for 89 (7.76%) nodes. Men had higher mean outdegree and women, higher betweenness. Delhi was the exogenous source of 17.44% cases. Bangalore city had the highest caseload in the state (229, 20%), but comparatively low cluster formation. Thirty-four (2.96%) super-spreaders (outdegree[&ge;]5) caused 60% of the transmissions. Real-time social network visualization can allow healthcare administrators to flag evolving hotspots and pinpoint key actors in transmission. Prioritizing these areas and individuals for rigorous containment could help minimize resource outlay and potentially achieve a significant reduction in COVID-19 transmission.","rel_num_authors":4,"rel_authors":[{"author_name":"Sakranaik Saraswathi","author_inst":"Bangalore Medical College and Research Institute, Bangalore, Karnataka, India."},{"author_name":"Amita Mukhopadhyay","author_inst":"Bangalore Medical College and Research Institute (former)"},{"author_name":"Hemant Shah","author_inst":"Independent researcher"},{"author_name":"T S Ranganath","author_inst":"Bangalore Medical College and Research Institute, Bangalore, Karnataka, India"},{"author_name":"Sabrina Di Stefano","author_inst":"Intensive Care Unit, Hospital Italiano de Buenos Aires"},{"author_name":"Valeria Burgos","author_inst":"Institute of translational medicine and biomedical engineering, Hospital Italiano de Buenos Aires, IUHI, CONICET"},{"author_name":"Jorge Federico Sinner","author_inst":"Intensive Care Unit, Hospital Italiano de Buenos Aires"},{"author_name":"Marcelo Raul Risk","author_inst":"Institute of translational medicine and biomedical engineering, Hospital Italiano de Buenos Aires, IUHI, CONICET"},{"author_name":"Eduardo San Roman","author_inst":"Intensive Care Unit, Hospital Italiano de Buenos Aires"},{"author_name":"Marcos Jose Las Heras","author_inst":"Intensive Care Unit, Hospital Italiano de Buenos Aires"},{"author_name":"Eduardo Marquez-Garcia","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Edda Sciutto","author_inst":"Instituto de Investigaciones Biomedicas, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico"},{"author_name":"Jose Moreno-Rodriguez","author_inst":"Hospital Juarez de Mexico, Mexico City, Mexico"},{"author_name":"Jose Omar Barreto-Rodriguez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Hazel Vazquez-Rojas","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Gustavo Ivan Centeno-Saenz","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael CosIo Villegas (INER), Mexico City, Mexico"},{"author_name":"Nestor Alvarado-Pena","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Citlaltepetl Salinas-Lara","author_inst":"Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez (INNyN), Mexico City, Mexico"},{"author_name":"Carlos Sanchez-Garibay","author_inst":"Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez (INNyN), Mexico City, Mexico"},{"author_name":"Gabriela Hernandez-Molina","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Criselda Mendoza-Milla","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Andrea Dominguez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Julio Granados","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Lula Mena-Hernandez","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Luis Angel Perez-Buenfil","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Guillermo Dominguez-Cheritt","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Carlos Cabello-Gutierrez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Cesar Luna-Rivero","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Jorge Salas-Hernandez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Patricio Santilla-Doherty","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Justino Regalado","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Angelica Hernandez-Martinez","author_inst":"Instituto Nacional de Medicina Genomica, Mexico City, Mexico"},{"author_name":"Lorena Orozco","author_inst":"Instituto Nacional de Medicina Genomica, Mexico City, Mexico"},{"author_name":"Ethel A. Garcia-Latorre","author_inst":"Escuela Nacional de Ciencias Biologicas, Instituto Politecnico Nacional, Mexico City, Mexico"},{"author_name":"Carmen M. Hernandez-Cardenas","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Shabaana A. Khader","author_inst":"Department of Molecular Microbiology, Washington University School of Medicine in St Louis, MO, United States"},{"author_name":"Albert Zlotnik","author_inst":"Department of Physiology & Biophysics School of Medicine, Institute for Immunology, University of California, Irvine, United-States"},{"author_name":"Joaquin Zuniga","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"}],"version":"1","license":"cc_by_nc_nd","type":"PUBLISHAHEADOFPRINT","category":"epidemiology"},{"rel_doi":"10.1101\/2020.08.12.20173831","rel_title":"Temporal Dynamics of Viral Load and False Negative Rate Influence the Levels of Testing Necessary to Combat COVID19 Spread","rel_date":"2020-08-14","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.12.20173831","rel_abs":"Colleges and other organizations are considering testing plans to return to operation as the COVID19 pandemic continues. Pre-symptomatic spread and high false negative rates for testing may make it difficult to stop viral spread. Here, we develop a stochastic agent-based model of COVID19 in a university sized population, considering the dynamics of both viral load and false negative rate of tests on the ability of testing to combat viral spread. Reported dynamics of SARS-CoV-2 can lead to an apparent false negative rate from ~17% to ~48%. Nonuniform distributions of viral load and false negative rate lead to higher requirements for frequency and fraction of population tested in order to bring the apparent Reproduction number (Rt) below 1. Thus, it is important to consider non-uniform dynamics of viral spread and false negative rate in order to model effective testing plans.","rel_num_authors":2,"rel_authors":[{"author_name":"Katherine F Jarvis","author_inst":"University of Maine"},{"author_name":"Joshua B Kelley","author_inst":"University of Maine"},{"author_name":"Hemant Shah","author_inst":"Independent researcher"},{"author_name":"T S Ranganath","author_inst":"Bangalore Medical College and Research Institute, Bangalore, Karnataka, India"},{"author_name":"Sabrina Di Stefano","author_inst":"Intensive Care Unit, Hospital Italiano de Buenos Aires"},{"author_name":"Valeria Burgos","author_inst":"Institute of translational medicine and biomedical engineering, Hospital Italiano de Buenos Aires, IUHI, CONICET"},{"author_name":"Jorge Federico Sinner","author_inst":"Intensive Care Unit, Hospital Italiano de Buenos Aires"},{"author_name":"Marcelo Raul Risk","author_inst":"Institute of translational medicine and biomedical engineering, Hospital Italiano de Buenos Aires, IUHI, CONICET"},{"author_name":"Eduardo San Roman","author_inst":"Intensive Care Unit, Hospital Italiano de Buenos Aires"},{"author_name":"Marcos Jose Las Heras","author_inst":"Intensive Care Unit, Hospital Italiano de Buenos Aires"},{"author_name":"Eduardo Marquez-Garcia","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Edda Sciutto","author_inst":"Instituto de Investigaciones Biomedicas, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico"},{"author_name":"Jose Moreno-Rodriguez","author_inst":"Hospital Juarez de Mexico, Mexico City, Mexico"},{"author_name":"Jose Omar Barreto-Rodriguez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Hazel Vazquez-Rojas","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Gustavo Ivan Centeno-Saenz","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael CosIo Villegas (INER), Mexico City, Mexico"},{"author_name":"Nestor Alvarado-Pena","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Citlaltepetl Salinas-Lara","author_inst":"Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez (INNyN), Mexico City, Mexico"},{"author_name":"Carlos Sanchez-Garibay","author_inst":"Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez (INNyN), Mexico City, Mexico"},{"author_name":"Gabriela Hernandez-Molina","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Criselda Mendoza-Milla","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Andrea Dominguez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Julio Granados","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Lula Mena-Hernandez","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Luis Angel Perez-Buenfil","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Guillermo Dominguez-Cheritt","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Carlos Cabello-Gutierrez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Cesar Luna-Rivero","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Jorge Salas-Hernandez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Patricio Santilla-Doherty","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Justino Regalado","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Angelica Hernandez-Martinez","author_inst":"Instituto Nacional de Medicina Genomica, Mexico City, Mexico"},{"author_name":"Lorena Orozco","author_inst":"Instituto Nacional de Medicina Genomica, Mexico City, Mexico"},{"author_name":"Ethel A. Garcia-Latorre","author_inst":"Escuela Nacional de Ciencias Biologicas, Instituto Politecnico Nacional, Mexico City, Mexico"},{"author_name":"Carmen M. Hernandez-Cardenas","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Shabaana A. Khader","author_inst":"Department of Molecular Microbiology, Washington University School of Medicine in St Louis, MO, United States"},{"author_name":"Albert Zlotnik","author_inst":"Department of Physiology & Biophysics School of Medicine, Institute for Immunology, University of California, Irvine, United-States"},{"author_name":"Joaquin Zuniga","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"}],"version":"1","license":"cc_by_nc_nd","type":"PUBLISHAHEADOFPRINT","category":"epidemiology"},{"rel_doi":"10.1101\/2020.08.12.20173674","rel_title":"Double-zero-event studies matter: a re-evaluation of physical distancing, face masks, and eye protection for preventing person-to-person transmission of COVID-19 and its policy impact","rel_date":"2020-08-14","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.12.20173674","rel_abs":"Objectives: High-quality meta-analyses on COVID-19 are in urgent demand for evidence-based decision making. However, conventional approaches exclude double-zero-event studies (DZS) from meta-analyses. We assessed whether including such studies impacts the conclusions in a recent systematic urgent review on prevention measures for preventing person-to-person transmission of COVID-19. Study designs and settings: We extracted data for meta-analyses containing DZS from a recent review that assessed the effects of physical distancing, face masks, and eye protection for preventing person-to-person transmission. A bivariate generalized linear mixed model was used to re-do the meta-analyses with DZS included. We compared the synthesized relative risks (RRs) of the three prevention measures, their 95% confidence intervals (CI), and significance tests (at the level of 0.05) including and excluding DZS. Results: The re-analyzed COVID-19 data containing DZS involved a total of 1,784 participants who were not considered in the original review. Including DZS noticeably changed the synthesized RRs and 95% CIs of several interventions. For the meta-analysis of the effect of physical distancing, the RR of COVID-19 decreased from 0.15 (95% CI, 0.03 to 0.73) to 0.07 (95% CI, 0.01 to 0.98). For several meta-analyses, the statistical significance of the synthesized RR was changed. The RR of eye protection with a physical distance of 2 m and the RR of physical distancing when using N95 respirators were no longer statistically significant after including DZS. Conclusions: DZS may contain useful information. Sensitivity analyses that include DZS in meta-analysis are recommended.","rel_num_authors":5,"rel_authors":[{"author_name":"Mengli Xiao","author_inst":"University of Minnesota"},{"author_name":"Lifeng Lin","author_inst":"Florida State University"},{"author_name":"James S. Hodges","author_inst":"University of Minnesota"},{"author_name":"Chang Xu","author_inst":"Qatar University"},{"author_name":"Haitao Chu","author_inst":"University of Minnesota"},{"author_name":"Valeria Burgos","author_inst":"Institute of translational medicine and biomedical engineering, Hospital Italiano de Buenos Aires, IUHI, CONICET"},{"author_name":"Jorge Federico Sinner","author_inst":"Intensive Care Unit, Hospital Italiano de Buenos Aires"},{"author_name":"Marcelo Raul Risk","author_inst":"Institute of translational medicine and biomedical engineering, Hospital Italiano de Buenos Aires, IUHI, CONICET"},{"author_name":"Eduardo San Roman","author_inst":"Intensive Care Unit, Hospital Italiano de Buenos Aires"},{"author_name":"Marcos Jose Las Heras","author_inst":"Intensive Care Unit, Hospital Italiano de Buenos Aires"},{"author_name":"Eduardo Marquez-Garcia","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Edda Sciutto","author_inst":"Instituto de Investigaciones Biomedicas, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico"},{"author_name":"Jose Moreno-Rodriguez","author_inst":"Hospital Juarez de Mexico, Mexico City, Mexico"},{"author_name":"Jose Omar Barreto-Rodriguez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Hazel Vazquez-Rojas","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Gustavo Ivan Centeno-Saenz","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael CosIo Villegas (INER), Mexico City, Mexico"},{"author_name":"Nestor Alvarado-Pena","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Citlaltepetl Salinas-Lara","author_inst":"Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez (INNyN), Mexico City, Mexico"},{"author_name":"Carlos Sanchez-Garibay","author_inst":"Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez (INNyN), Mexico City, Mexico"},{"author_name":"Gabriela Hernandez-Molina","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Criselda Mendoza-Milla","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Andrea Dominguez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Julio Granados","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Lula Mena-Hernandez","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Luis Angel Perez-Buenfil","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Guillermo Dominguez-Cheritt","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Carlos Cabello-Gutierrez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Cesar Luna-Rivero","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Jorge Salas-Hernandez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Patricio Santilla-Doherty","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Justino Regalado","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Angelica Hernandez-Martinez","author_inst":"Instituto Nacional de Medicina Genomica, Mexico City, Mexico"},{"author_name":"Lorena Orozco","author_inst":"Instituto Nacional de Medicina Genomica, Mexico City, Mexico"},{"author_name":"Ethel A. Garcia-Latorre","author_inst":"Escuela Nacional de Ciencias Biologicas, Instituto Politecnico Nacional, Mexico City, Mexico"},{"author_name":"Carmen M. Hernandez-Cardenas","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Shabaana A. Khader","author_inst":"Department of Molecular Microbiology, Washington University School of Medicine in St Louis, MO, United States"},{"author_name":"Albert Zlotnik","author_inst":"Department of Physiology & Biophysics School of Medicine, Institute for Immunology, University of California, Irvine, United-States"},{"author_name":"Joaquin Zuniga","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"}],"version":"1","license":"cc_no","type":"PUBLISHAHEADOFPRINT","category":"epidemiology"},{"rel_doi":"10.1101\/2020.08.12.20170852","rel_title":"knowledge, attitudes and practices (KAP) towards Covid-19 among Palestinians during the Covid-19 outbreak: a cross sectional survey","rel_date":"2020-08-14","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.12.20170852","rel_abs":"Coronavirus disease 2019 (COVID19) is a highly contagious illness that spreads rapidly through human to human transmission. On March 5, the government of Palestine declared a state of emergency in order to curb the spread of the virus, a declaration that it extended for a fifth time on July 5th. The degree to which a population complies with corresponding safety measures is surely affected by the people's knowledge, attitudes and practices (KAP) towards the disease. To explore this hypothesis, we gathered data from 1,731 Palestinians between April 19th and May 1st, 2020 through a KAP questionnaire. The participant pool represented a stratified sample of Palestinians living across a number of governorates in the Gaza Strip and the West Bank, with 36.5% from Gaza and (63.5%) from the West Bank. Gender was almost equally distributed within the sample with (51%) male respondents and (49%) female respondent. The questionnaire included 17 questions about participants knowledge and awareness of COVID19, 17 questions regarding the safety measures they had taken in the wake of the outbreak and 3 questions asking them to assess the efficacy of the governments response to the pandemic. The overall correct mean of the knowledge was 79.26+-0.35. Most participants' expressed confidence that Covid19 would be successfully controlled and that Palestine could win the battle against Covid19, though 62% believed that stricter measurements must be applied. Based on the results of this study, we conclude that health education programs aimed at improving the public's understanding of COVID19 are important in helping the population maintain appropriate practices, and that findings such as those discussed in this report may provide valuable feedback to lawmakers working to stop the spread of the virus.","rel_num_authors":2,"rel_authors":[{"author_name":"Nouar Qutob","author_inst":"Arab American University"},{"author_name":"Faisal Awartani","author_inst":"Arab American Universiry"},{"author_name":"James S. Hodges","author_inst":"University of Minnesota"},{"author_name":"Chang Xu","author_inst":"Qatar University"},{"author_name":"Haitao Chu","author_inst":"University of Minnesota"},{"author_name":"Valeria Burgos","author_inst":"Institute of translational medicine and biomedical engineering, Hospital Italiano de Buenos Aires, IUHI, CONICET"},{"author_name":"Jorge Federico Sinner","author_inst":"Intensive Care Unit, Hospital Italiano de Buenos Aires"},{"author_name":"Marcelo Raul Risk","author_inst":"Institute of translational medicine and biomedical engineering, Hospital Italiano de Buenos Aires, IUHI, CONICET"},{"author_name":"Eduardo San Roman","author_inst":"Intensive Care Unit, Hospital Italiano de Buenos Aires"},{"author_name":"Marcos Jose Las Heras","author_inst":"Intensive Care Unit, Hospital Italiano de Buenos Aires"},{"author_name":"Eduardo Marquez-Garcia","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Edda Sciutto","author_inst":"Instituto de Investigaciones Biomedicas, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico"},{"author_name":"Jose Moreno-Rodriguez","author_inst":"Hospital Juarez de Mexico, Mexico City, Mexico"},{"author_name":"Jose Omar Barreto-Rodriguez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Hazel Vazquez-Rojas","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Gustavo Ivan Centeno-Saenz","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael CosIo Villegas (INER), Mexico City, Mexico"},{"author_name":"Nestor Alvarado-Pena","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Citlaltepetl Salinas-Lara","author_inst":"Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez (INNyN), Mexico City, Mexico"},{"author_name":"Carlos Sanchez-Garibay","author_inst":"Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez (INNyN), Mexico City, Mexico"},{"author_name":"Gabriela Hernandez-Molina","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Criselda Mendoza-Milla","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Andrea Dominguez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Julio Granados","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Lula Mena-Hernandez","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Luis Angel Perez-Buenfil","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Guillermo Dominguez-Cheritt","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Carlos Cabello-Gutierrez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Cesar Luna-Rivero","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Jorge Salas-Hernandez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Patricio Santilla-Doherty","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Justino Regalado","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Angelica Hernandez-Martinez","author_inst":"Instituto Nacional de Medicina Genomica, Mexico City, Mexico"},{"author_name":"Lorena Orozco","author_inst":"Instituto Nacional de Medicina Genomica, Mexico City, Mexico"},{"author_name":"Ethel A. Garcia-Latorre","author_inst":"Escuela Nacional de Ciencias Biologicas, Instituto Politecnico Nacional, Mexico City, Mexico"},{"author_name":"Carmen M. Hernandez-Cardenas","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Shabaana A. Khader","author_inst":"Department of Molecular Microbiology, Washington University School of Medicine in St Louis, MO, United States"},{"author_name":"Albert Zlotnik","author_inst":"Department of Physiology & Biophysics School of Medicine, Institute for Immunology, University of California, Irvine, United-States"},{"author_name":"Joaquin Zuniga","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"}],"version":"1","license":"cc_no","type":"PUBLISHAHEADOFPRINT","category":"epidemiology"},{"rel_doi":"10.1101\/2020.08.11.20173120","rel_title":"Network reinforcement driven drug repurposing for COVID-19 by exploiting disease-gene-drug associations","rel_date":"2020-08-14","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.11.20173120","rel_abs":"Currently, the number of patients with COVID-19 has significantly increased. Thus, there is an urgent need for developing treatments for COVID-19. Drug repurposing, which is the process of reusing already-approved drugs for new medical conditions, can be a good way to solve this problem quickly and broadly. Many clinical trials for COVID-19 patients using treatments for other diseases have already been in place or will be performed at clinical sites in the near future. Additionally, patients with comorbidities such as diabetes mellitus, obesity, liver cirrhosis, kidney diseases, hypertension, and asthma are at higher risk for severe illness from COVID-19. Thus, the relationship of comorbidity disease with COVID-19 may help to find repurposable drugs. To reduce trial and error in finding treatments for COVID-19, we propose building a network-based drug repurposing framework to prioritize repurposable drugs. First, we utilized knowledge of COVID-19 to construct a disease-gene-drug network (DGDr-Net) representing a COVID-19-centric interactome with components for diseases, genes, and drugs. DGDr-Net consisted of 592 diseases, 26,681 human genes and 2,173 drugs, and medical information for 18 common comorbidities. The DGDr-Net recommended candidate repurposable drugs for COVID-19 through network reinforcement driven scoring algorithms. The scoring algorithms determined the priority of recommendations by utilizing graph-based semi-supervised learning. From the predicted scores, we recommended 30 drugs, including dexamethasone, resveratrol, methotrexate, indomethacin, quercetin, etc., as repurposable drugs for COVID-19, and the results were verified with drugs that have been under clinical trials. The list of drugs via a data-driven computational approach could help reduce trial-and-error in finding treatment for COVID-19.","rel_num_authors":10,"rel_authors":[{"author_name":"Yonghyun Nam","author_inst":"University of Pennsylvania"},{"author_name":"Jae-Seung Yun","author_inst":"University of Pennsylvania"},{"author_name":"Seung Mi Lee","author_inst":"University of Pennsylvania"},{"author_name":"Ji Won Park","author_inst":"University of Pennsylvania"},{"author_name":"Ziqi Chen","author_inst":"The Ohio State University"},{"author_name":"Brian Lee","author_inst":"University of Pennsylvania"},{"author_name":"Anurag Verma","author_inst":"University of Pennsylvania"},{"author_name":"Xia Ning","author_inst":"The Ohio State University"},{"author_name":"Li Shen","author_inst":"University of Pennsylvania"},{"author_name":"Dokyoon Kim","author_inst":"University of Pennsylvania"},{"author_name":"Eduardo Marquez-Garcia","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Edda Sciutto","author_inst":"Instituto de Investigaciones Biomedicas, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico"},{"author_name":"Jose Moreno-Rodriguez","author_inst":"Hospital Juarez de Mexico, Mexico City, Mexico"},{"author_name":"Jose Omar Barreto-Rodriguez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Hazel Vazquez-Rojas","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Gustavo Ivan Centeno-Saenz","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael CosIo Villegas (INER), Mexico City, Mexico"},{"author_name":"Nestor Alvarado-Pena","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Citlaltepetl Salinas-Lara","author_inst":"Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez (INNyN), Mexico City, Mexico"},{"author_name":"Carlos Sanchez-Garibay","author_inst":"Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez (INNyN), Mexico City, Mexico"},{"author_name":"Gabriela Hernandez-Molina","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Criselda Mendoza-Milla","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Andrea Dominguez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Julio Granados","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Lula Mena-Hernandez","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Luis Angel Perez-Buenfil","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Guillermo Dominguez-Cheritt","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Carlos Cabello-Gutierrez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Cesar Luna-Rivero","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Jorge Salas-Hernandez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Patricio Santilla-Doherty","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Justino Regalado","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Angelica Hernandez-Martinez","author_inst":"Instituto Nacional de Medicina Genomica, Mexico City, Mexico"},{"author_name":"Lorena Orozco","author_inst":"Instituto Nacional de Medicina Genomica, Mexico City, Mexico"},{"author_name":"Ethel A. Garcia-Latorre","author_inst":"Escuela Nacional de Ciencias Biologicas, Instituto Politecnico Nacional, Mexico City, Mexico"},{"author_name":"Carmen M. Hernandez-Cardenas","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Shabaana A. Khader","author_inst":"Department of Molecular Microbiology, Washington University School of Medicine in St Louis, MO, United States"},{"author_name":"Albert Zlotnik","author_inst":"Department of Physiology & Biophysics School of Medicine, Institute for Immunology, University of California, Irvine, United-States"},{"author_name":"Joaquin Zuniga","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"}],"version":"1","license":"cc_by_nc_nd","type":"PUBLISHAHEADOFPRINT","category":"pharmacology and therapeutics"},{"rel_doi":"10.1101\/2020.08.12.20173468","rel_title":"Immediate Effects of COVID-19 Outbreak on Psychiatric Outpatients: Posttraumatic Stress and Influencing Factors","rel_date":"2020-08-14","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.12.20173468","rel_abs":"We aimed to investigate the effects of COVID-19 outbreak and public health measures on the psychological well-being of patients with psychiatric disorders. This cross-sectional study assessed 436 outpatients recruited from a tertiary psychiatry clinic in Istanbul, Turkey, nearly one month after the government introduced strict measures of lockdown against the ongoing outbreak. Respondents completed a web-based survey on sociodemographic data, subjective sleep quality, and a range of psychiatric symptoms using the Impact of Events Scale-Revised (IES-R), and Hospital Anxiety and Depression Scale (HADS). Respondents reported high frequencies of clinically significant posttraumatic stress disorder (PTSD) (32.6%, IES-R score equal to or above 33), anxiety (36.4%, HADS anxiety score > 10), and depression (51%, HADS depression score > 10). 20.5% of respondents described that their psychological status worsened during the COVID-19 outbreak, and 12.1% of respondents described poor or very poor sleep in the prior month. Positive predictors of increased PTSD symptoms included the chronic medical diseases, knowing someone in the social vicinity diagnosed with the COVID-19 infection, job loss or being on temporary leave after the outbreak, and increased exposure time to TV or social media. In contrast, male gender, older age, higher educational attainment, and the psychiatric diagnoses of schizophrenia and (to a lesser degree) bipolar disorder were the negative predictors. Our results suggest that patients with psychiatric disorders are prone to substantial psychological distress during the COVID-19 outbreak, and various individual, behavioral, and social factors mediate this effect.","rel_num_authors":8,"rel_authors":[{"author_name":"Burc Cagri Poyraz","author_inst":"Department of Psychiatry, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey."},{"author_name":"Cana Aksoy Poyraz","author_inst":"Department of Psychiatry, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey."},{"author_name":"Senol Turan","author_inst":"Department of Psychiatry, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey."},{"author_name":"Omer Faruk Demirel","author_inst":"Department of Psychiatry, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey."},{"author_name":"Yasin Kavla","author_inst":"Department of Psychiatry, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey."},{"author_name":"Ersel Bulu","author_inst":"Department of Psychiatry, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey."},{"author_name":"Irem Hacisalihoglu","author_inst":"Department of Psychiatry, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey."},{"author_name":"Elif Burcu Ersungur","author_inst":"Department of Psychiatry, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey."},{"author_name":"Li Shen","author_inst":"University of Pennsylvania"},{"author_name":"Dokyoon Kim","author_inst":"University of Pennsylvania"},{"author_name":"Eduardo Marquez-Garcia","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Edda Sciutto","author_inst":"Instituto de Investigaciones Biomedicas, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico"},{"author_name":"Jose Moreno-Rodriguez","author_inst":"Hospital Juarez de Mexico, Mexico City, Mexico"},{"author_name":"Jose Omar Barreto-Rodriguez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Hazel Vazquez-Rojas","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Gustavo Ivan Centeno-Saenz","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael CosIo Villegas (INER), Mexico City, Mexico"},{"author_name":"Nestor Alvarado-Pena","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Citlaltepetl Salinas-Lara","author_inst":"Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez (INNyN), Mexico City, Mexico"},{"author_name":"Carlos Sanchez-Garibay","author_inst":"Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez (INNyN), Mexico City, Mexico"},{"author_name":"Gabriela Hernandez-Molina","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Criselda Mendoza-Milla","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Andrea Dominguez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Julio Granados","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Lula Mena-Hernandez","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Luis Angel Perez-Buenfil","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Guillermo Dominguez-Cheritt","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Carlos Cabello-Gutierrez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Cesar Luna-Rivero","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Jorge Salas-Hernandez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Patricio Santilla-Doherty","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Justino Regalado","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Angelica Hernandez-Martinez","author_inst":"Instituto Nacional de Medicina Genomica, Mexico City, Mexico"},{"author_name":"Lorena Orozco","author_inst":"Instituto Nacional de Medicina Genomica, Mexico City, Mexico"},{"author_name":"Ethel A. Garcia-Latorre","author_inst":"Escuela Nacional de Ciencias Biologicas, Instituto Politecnico Nacional, Mexico City, Mexico"},{"author_name":"Carmen M. Hernandez-Cardenas","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Shabaana A. Khader","author_inst":"Department of Molecular Microbiology, Washington University School of Medicine in St Louis, MO, United States"},{"author_name":"Albert Zlotnik","author_inst":"Department of Physiology & Biophysics School of Medicine, Institute for Immunology, University of California, Irvine, United-States"},{"author_name":"Joaquin Zuniga","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"}],"version":"1","license":"cc_by_nc_nd","type":"PUBLISHAHEADOFPRINT","category":"psychiatry and clinical psychology"},{"rel_doi":"10.1101\/2020.08.12.20173476","rel_title":"Superspreading k-cores at the center of COVID-19 pandemic persistence","rel_date":"2020-08-14","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.12.20173476","rel_abs":"The spread of COVID-19 caused by the recently discovered SARS-CoV-2 virus has become a worldwide problem with devastating consequences. To slow down the spread of the pandemic, mass quarantines have been implemented globally, provoking further social and economic disruptions. Here, we address this problem by implementing a large-scale contact tracing network analysis to find the optimal quarantine protocol to dismantle the chain of transmission of coronavirus with minimal disruptions to society. We track billions of anonymized GPS human mobility datapoints from a compilation of hundreds of mobile apps deployed in Latin America to monitor the evolution of the contact network of disease transmission before and after the confinements. As a consequence of the lockdowns, people's mobility across the region decreases by ~53%, which results in a drastic disintegration of the transmission network by ~90%. However, this disintegration did not halt the spreading of the disease. Our analysis indicates that superspreading k-core structures persist in the transmission network to prolong the pandemic. Once the k-cores are identified, the optimal strategy to break the chain of transmission is to quarantine a minimal number of 'weak links' with high betweenness centrality connecting the large k-cores. Our results demonstrate the effectiveness of an optimal tracing strategy to halt the pandemic. As countries race to build and deploy contact tracing apps, our results could turn into a valuable resource to help deploy protocols with minimized disruptions.","rel_num_authors":9,"rel_authors":[{"author_name":"Matteo Serafino","author_inst":"Levich Institute and Physics Department, City College   of New York, New York, NY 10031, USA and IMT School for Advanced Studies, 55100 Lucca, Italy"},{"author_name":"Higor S. Monteiro","author_inst":"Departamento de F\u00edsica, Universidade Federal do Cear\u00e1, 60451-970 Fortaleza, Cear\u00e1, Brazil"},{"author_name":"Shaojun Luo","author_inst":"Levich Institute and Physics Department, City College   of New York, New York, NY 10031, USA"},{"author_name":"Saulo D. S. Reis","author_inst":"Departamento de F\u00edsica, Universidade Federal do Cear\u00e1, 60451-970 Fortaleza, Cear\u00e1, Brazil"},{"author_name":"Carles Igual","author_inst":"Instituto de Telecomunicaciones y Aplicaciones Multimedia (ITEAM), Departamento de Comunicaciones, Universitat Polit\u00e8cnica de Val\u00e8ncia, Val\u00e8ncia 46022, Spain"},{"author_name":"Antonio S. Lima Neto","author_inst":"Department of Epidemiological Surveillance, Fortaleza Health Secretariat,  Fortaleza, Cear\u00e1, Brazil and Department of Public Health, University of Fortaleza Med"},{"author_name":"Mat\u00edas Travizano","author_inst":"Grandata, Inc, 550 15th St. Suite 36, San Francisco, CA 94103, USA"},{"author_name":"Jos\u00e9 S. Andrade Jr.","author_inst":"Departamento de F\u00edsica, Universidade Federal do Cear\u00e1, 60451-970 Fortaleza, Cear\u00e1, Brazil"},{"author_name":"Hern\u00e1n A. Makse","author_inst":"Levich Institute and Physics Department, City College   of New York, New York, NY 10031, USA"},{"author_name":"Dokyoon Kim","author_inst":"University of Pennsylvania"},{"author_name":"Eduardo Marquez-Garcia","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Edda Sciutto","author_inst":"Instituto de Investigaciones Biomedicas, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico"},{"author_name":"Jose Moreno-Rodriguez","author_inst":"Hospital Juarez de Mexico, Mexico City, Mexico"},{"author_name":"Jose Omar Barreto-Rodriguez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Hazel Vazquez-Rojas","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Gustavo Ivan Centeno-Saenz","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael CosIo Villegas (INER), Mexico City, Mexico"},{"author_name":"Nestor Alvarado-Pena","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Citlaltepetl Salinas-Lara","author_inst":"Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez (INNyN), Mexico City, Mexico"},{"author_name":"Carlos Sanchez-Garibay","author_inst":"Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez (INNyN), Mexico City, Mexico"},{"author_name":"Gabriela Hernandez-Molina","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Criselda Mendoza-Milla","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Andrea Dominguez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Julio Granados","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Lula Mena-Hernandez","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Luis Angel Perez-Buenfil","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Guillermo Dominguez-Cheritt","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Carlos Cabello-Gutierrez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Cesar Luna-Rivero","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Jorge Salas-Hernandez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Patricio Santilla-Doherty","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Justino Regalado","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Angelica Hernandez-Martinez","author_inst":"Instituto Nacional de Medicina Genomica, Mexico City, Mexico"},{"author_name":"Lorena Orozco","author_inst":"Instituto Nacional de Medicina Genomica, Mexico City, Mexico"},{"author_name":"Ethel A. Garcia-Latorre","author_inst":"Escuela Nacional de Ciencias Biologicas, Instituto Politecnico Nacional, Mexico City, Mexico"},{"author_name":"Carmen M. Hernandez-Cardenas","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Shabaana A. Khader","author_inst":"Department of Molecular Microbiology, Washington University School of Medicine in St Louis, MO, United States"},{"author_name":"Albert Zlotnik","author_inst":"Department of Physiology & Biophysics School of Medicine, Institute for Immunology, University of California, Irvine, United-States"},{"author_name":"Joaquin Zuniga","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"}],"version":"1","license":"cc_by","type":"PUBLISHAHEADOFPRINT","category":"public and global health"},{"rel_doi":"10.1101\/2020.08.12.20157271","rel_title":"ASSOCIATION BETWEEN ETHNICITY AND SEVERE COVID-19 DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS.","rel_date":"2020-08-14","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.12.20157271","rel_abs":"Background: Multiple reports suggested disproportionate impact of Covid-19 on ethnic minorities. Whether ethnicity is an independent risk factor for severe Covid-19 illness is unclear. Purpose: Review the association between ethnicity and poor Covid-19 outcomes including all-cause mortality, hospitalisation, critical care admission, respiratory and kidney failure. Data Sources: MEDLINE, EMBASE, Cochrane COVID-19 Study Register, WHO COVID-19 Global Research Database up to 15\/06\/2020, and preprint servers. No language restriction. Study Selection: All studies providing ethnicity-aggregated data on the pre-specified outcomes, except case reports or interventional trials Data Extraction: Pairs of investigators independently extracted data, assessed risk of bias using Newcastle-Ottawa scale (NOS), and rated certainty of evidence following GRADE framework. Data Synthesis: Seventy-two articles (59 cohort studies with 17,950,989 participants; 13 ecological studies; 54 US-based and 15 UK-based; 41 peer-reviewed) were included for systematic review and 45 for meta-analyses. Risk of bias was low, with median NOS of 7 (interquartile range 6-8). In the unadjusted analyses, compared to white ethnicity, all-cause mortality risk was similar in Black (RR:0.96 [95%CI: 0.83-1.08]), Asian (RR:0.99 [0.85-1.16]) but reduced in Hispanic ethnicity (RR:0.69 [0.57-0.84]). Age and sex-adjusted-risks were significantly elevated for Black (HR:1.38 [1.09-1.75]) and Asian (HR:1.42 [1.15-1.75]), but not for Hispanic (RR:1.14 [0.93-1.40]). Further adjusting for comorbidities attenuated these association to non-significance; Black (HR:0.95 [0.72-1.25]); Asian (HR:1.17 [0.84-1.63]); Hispanic (HR:0.94 [0.63-1.44]). Similar results were observed for other outcomes. In subgroup analysis, there is a trend towards greater disparity in outcomes for UK ethnic minorities, especially hospitalisation risks. Limitations: Paucity of evidence on native ethnic groups, and studies outside US and UK. Conclusions: Currently available evidence cannot confirm ethnicity as an independent risk factor for severe Covid-19 illness, but indicates that disparity may be partially attributed to greater burden of comorbidities. Registration: PROSPERO, CRD42020188421 Funding source: none","rel_num_authors":3,"rel_authors":[{"author_name":"Antony Raharja","author_inst":"Guys and St Thomas NHS Foundation Trust, London, UK"},{"author_name":"Alice Tamara","author_inst":"Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia"},{"author_name":"Li Teng Kok","author_inst":"Guys and St Thomas NHS Foundation Trust, London, UK"},{"author_name":"Saulo D. S. Reis","author_inst":"Departamento de F\u00edsica, Universidade Federal do Cear\u00e1, 60451-970 Fortaleza, Cear\u00e1, Brazil"},{"author_name":"Carles Igual","author_inst":"Instituto de Telecomunicaciones y Aplicaciones Multimedia (ITEAM), Departamento de Comunicaciones, Universitat Polit\u00e8cnica de Val\u00e8ncia, Val\u00e8ncia 46022, Spain"},{"author_name":"Antonio S. Lima Neto","author_inst":"Department of Epidemiological Surveillance, Fortaleza Health Secretariat,  Fortaleza, Cear\u00e1, Brazil and Department of Public Health, University of Fortaleza Med"},{"author_name":"Mat\u00edas Travizano","author_inst":"Grandata, Inc, 550 15th St. Suite 36, San Francisco, CA 94103, USA"},{"author_name":"Jos\u00e9 S. Andrade Jr.","author_inst":"Departamento de F\u00edsica, Universidade Federal do Cear\u00e1, 60451-970 Fortaleza, Cear\u00e1, Brazil"},{"author_name":"Hern\u00e1n A. Makse","author_inst":"Levich Institute and Physics Department, City College   of New York, New York, NY 10031, USA"},{"author_name":"Dokyoon Kim","author_inst":"University of Pennsylvania"},{"author_name":"Eduardo Marquez-Garcia","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Edda Sciutto","author_inst":"Instituto de Investigaciones Biomedicas, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico"},{"author_name":"Jose Moreno-Rodriguez","author_inst":"Hospital Juarez de Mexico, Mexico City, Mexico"},{"author_name":"Jose Omar Barreto-Rodriguez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Hazel Vazquez-Rojas","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Gustavo Ivan Centeno-Saenz","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael CosIo Villegas (INER), Mexico City, Mexico"},{"author_name":"Nestor Alvarado-Pena","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Citlaltepetl Salinas-Lara","author_inst":"Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez (INNyN), Mexico City, Mexico"},{"author_name":"Carlos Sanchez-Garibay","author_inst":"Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez (INNyN), Mexico City, Mexico"},{"author_name":"Gabriela Hernandez-Molina","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Criselda Mendoza-Milla","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Andrea Dominguez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Julio Granados","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Lula Mena-Hernandez","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Luis Angel Perez-Buenfil","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Guillermo Dominguez-Cheritt","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Carlos Cabello-Gutierrez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Cesar Luna-Rivero","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Jorge Salas-Hernandez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Patricio Santilla-Doherty","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Justino Regalado","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Angelica Hernandez-Martinez","author_inst":"Instituto Nacional de Medicina Genomica, Mexico City, Mexico"},{"author_name":"Lorena Orozco","author_inst":"Instituto Nacional de Medicina Genomica, Mexico City, Mexico"},{"author_name":"Ethel A. Garcia-Latorre","author_inst":"Escuela Nacional de Ciencias Biologicas, Instituto Politecnico Nacional, Mexico City, Mexico"},{"author_name":"Carmen M. Hernandez-Cardenas","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Shabaana A. Khader","author_inst":"Department of Molecular Microbiology, Washington University School of Medicine in St Louis, MO, United States"},{"author_name":"Albert Zlotnik","author_inst":"Department of Physiology & Biophysics School of Medicine, Institute for Immunology, University of California, Irvine, United-States"},{"author_name":"Joaquin Zuniga","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"}],"version":"1","license":"cc_by_nc_nd","type":"PUBLISHAHEADOFPRINT","category":"public and global health"},{"rel_doi":"10.1101\/2020.08.12.20173526","rel_title":"Patient outcomes after hospitalisation with COVID-19 and implications for follow-up; results from a prospective UK cohort.","rel_date":"2020-08-14","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.12.20173526","rel_abs":"Background: COVID19 causes a wide spectrum of disease. However, the incidence and severity of sequelae after the acute infection is uncertain. Data measuring the longer-term impact of COVID19 on symptoms, radiology and pulmonary function are urgently needed to inform patients and plan follow up services. Methods: Consecutive patients hospitalised with COVID19 were prospectively recruited to an observational cohort with outcomes recorded at 28 days. All were invited to a systematic follow up at 12 weeks, including chest radiograph, spirometry, exercise test, blood tests, and health-related quality of life (HRQoL) questionnaires. Findings: Between 30th March and 3rd June 2020, 163 patients with COVID19 were recruited. Median hospital length of stay was 5 days (IQR 2 to 8) and 30 patients required ITU or NIV, 19 patients died. At 12 weeks post admission, 134 were available for follow up and 110 attended. Most (74%) had persistent symptoms (notably breathlessness and excessive fatigue) with reduced HRQoL. Only patients with disease sufficiently severe to warrant oxygen therapy in hospital had abnormal radiology, clinical examination or spirometry at follow up. Thirteen (12%) patients had an abnormal chest X-ray with improvement in all but 2 from admission. Eleven (10%) had restrictive spirometry. Blood test abnormalities had returned to baseline in the majority (104\/110). Interpretation: Patients with COVID19 remain highly symptomatic at 12 weeks, however, clinical abnormalities requiring action are infrequent, especially in those without a supplementary oxygen requirement during their acute illness. This has significant implications for physicians assessing patients with persistent symptoms, suggesting that a more holistic approach focussing on rehabilitation and general wellbeing is paramount. Funding: Southmead Hospital Charity","rel_num_authors":18,"rel_authors":[{"author_name":"David T Arnold","author_inst":"Academic Respiratory Unit, North Bristol NHS Trust, Bristol, UK"},{"author_name":"Fergus W Hamilton","author_inst":"Academic Respiratory Unit, North Bristol NHS Trust, Bristol, UK"},{"author_name":"Alice Milne","author_inst":"Academic Respiratory Unit, North Bristol NHS Trust, Bristol, UK"},{"author_name":"Anna Morley","author_inst":"Academic Respiratory Unit, North Bristol NHS Trust, Bristol, UK"},{"author_name":"Jason Viner","author_inst":"Academic Respiratory Unit, North Bristol NHS Trust, Bristol, UK"},{"author_name":"Marie Attwood","author_inst":"Bristol Centre for Antimicrobial Research (BCARE), North Bristol NHS Trust, UK"},{"author_name":"Alan Noel","author_inst":"Bristol Centre for Antimicrobial Research (BCARE), North Bristol NHS Trust, UK"},{"author_name":"Samuel Gunning","author_inst":"Academic Respiratory Unit, North Bristol NHS Trust, Bristol, UK"},{"author_name":"Jessica Hatrick","author_inst":"Academic Respiratory Unit, North Bristol NHS Trust, Bristol, UK"},{"author_name":"Sassa Hamilton","author_inst":"Academic Respiratory Unit, North Bristol NHS Trust, Bristol, UK"},{"author_name":"Karen T Elvers","author_inst":"Medicines Discovery Institute Cardiff, Cardiff University, Park Place, Cardiff"},{"author_name":"Catherine Hyams","author_inst":"Academic Respiratory Unit, North Bristol NHS Trust, Bristol, UK"},{"author_name":"Anna Bibby","author_inst":"Academic Respiratory Unit, North Bristol NHS Trust, Bristol, UK"},{"author_name":"Ed Moran","author_inst":"Academic Respiratory Unit, North Bristol NHS Trust, Bristol, UK"},{"author_name":"Huzaifa Adamali","author_inst":"Academic Respiratory Unit, North Bristol NHS Trust, Bristol, UK"},{"author_name":"James Dodd","author_inst":"Academic Respiratory Unit, North Bristol NHS Trust, Bristol, UK"},{"author_name":"Nick A Maskell","author_inst":"Academic Respiratory Unit, North Bristol NHS Trust, Bristol, UK"},{"author_name":"Shaney Barratt","author_inst":"Academic Respiratory Unit, North Bristol NHS Trust, Bristol, UK"},{"author_name":"Carlos Sanchez-Garibay","author_inst":"Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez (INNyN), Mexico City, Mexico"},{"author_name":"Gabriela Hernandez-Molina","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Criselda Mendoza-Milla","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Andrea Dominguez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Julio Granados","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Lula Mena-Hernandez","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Luis Angel Perez-Buenfil","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Guillermo Dominguez-Cheritt","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Carlos Cabello-Gutierrez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Cesar Luna-Rivero","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Jorge Salas-Hernandez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Patricio Santilla-Doherty","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Justino Regalado","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Angelica Hernandez-Martinez","author_inst":"Instituto Nacional de Medicina Genomica, Mexico City, Mexico"},{"author_name":"Lorena Orozco","author_inst":"Instituto Nacional de Medicina Genomica, Mexico City, Mexico"},{"author_name":"Ethel A. Garcia-Latorre","author_inst":"Escuela Nacional de Ciencias Biologicas, Instituto Politecnico Nacional, Mexico City, Mexico"},{"author_name":"Carmen M. Hernandez-Cardenas","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Shabaana A. Khader","author_inst":"Department of Molecular Microbiology, Washington University School of Medicine in St Louis, MO, United States"},{"author_name":"Albert Zlotnik","author_inst":"Department of Physiology & Biophysics School of Medicine, Institute for Immunology, University of California, Irvine, United-States"},{"author_name":"Joaquin Zuniga","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"}],"version":"1","license":"cc_by_nc_nd","type":"PUBLISHAHEADOFPRINT","category":"respiratory medicine"},{"rel_doi":"10.1101\/2020.08.12.20171694","rel_title":"Universal screening for SARS-CoV-2 infection among pregnant women at Elmhurst Hospital Center, Queens, New York","rel_date":"2020-08-14","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.12.20171694","rel_abs":"Background Universal screening for SARS-CoV-2 infection on Labor and Delivery (L&D) units is a critical strategy to manage patient and health worker safety, especially in a vulnerable high-prevalence community. We describe the results of a SARS-CoV-2 universal screening program at the L&D Unit at Elmhurst Hospital in Queens, NY, a 545-bed public hospital serving a diverse, largely immigrant and low-income patient population and an epicenter of the global pandemic. Methods and findings We conducted a retrospective cross-sectional study. All pregnant women admitted to the L&D Unit of Elmhurst Hospital from March 29, 2020 to April 22, 2020 were included for analysis. The primary outcomes of the study were: (1) SARS-CoV-2 positivity among universally screened pregnant women, stratified by demographic characteristics, maternal comorbidities, and delivery outcomes; and (2) Symptomatic or asymptomatic presentation at the time of testing among SARS-CoV-2 positive women. A total of 126 obstetric patients were screened for SARS-CoV-2 between March 29 and April 22. Of these, 37% were positive. Of the women who tested positive, 72% were asymptomatic at the time of testing. Patients who tested positive for SARS-CoV-2 were more likely to be of Hispanic ethnicity (unadjusted difference 24.4 percentage points, CI 7.9, 41.0) and report their primary language as Spanish (unadjusted difference 32.9 percentage points, CI 15.8, 49.9) than patients who tested negative. Conclusions In this retrospective cross-sectional study of data from a universal SARS-Cov-2 screening program implemented in the L&D unit of a safety-net hospital in Queens, New York, we found over one-third of pregnant women testing positive, the majority of those asymptomatic. The rationale for universal screening at the L&D Unit at Elmhurst Hospital was to ensure safety of patients and staff during an acute surge in SARS-Cov-2 infections through appropriate identification and isolation of pregnant women with positive test results. Women were roomed by their SARS-CoV-2 status given increasing space limitations. In addition, postpartum counseling was tailored to infection status. We quickly established discharge counseling and follow-up protocols tailored to their specific social needs. The experience at Elmhurst Hospital is instructive for other L&D units serving vulnerable populations and for pandemic preparedness.","rel_num_authors":16,"rel_authors":[{"author_name":"Sheela Maru","author_inst":"Icahn School of Medicine at Mount Sinai and New York City Health + Hospitals\/Elmhurst"},{"author_name":"Uday Patil","author_inst":"Icahn School of Medicine at Mount Sinai and New York City Health + Hospitals\/Elmhurst"},{"author_name":"Rachel Carroll-Bennett","author_inst":"Icahn School of Medicine at Mount Sinai and New York City Health + Hospitals\/Elmhurst"},{"author_name":"Aaron Baum","author_inst":"Icahn School of Medicine at Mount Sinai"},{"author_name":"Tracy Bohn-Hemmerdinger","author_inst":"Icahn School of Medicine at Mount Sinai and New York City Health + Hospitals\/Elmhurst"},{"author_name":"Andrew Ditchik","author_inst":"Icahn School of Medicine at Mount Sinai and New York City Health + Hospitals\/Elmhurst"},{"author_name":"Michael Scanlon","author_inst":"Icahn School of Medicine at Mount Sinai"},{"author_name":"Parvathy Krishnan","author_inst":"Icahn School of Medicine at Mount Sinai and New York City Health + Hospitals\/Elmhurst"},{"author_name":"Kelly Bogaert","author_inst":"Icahn School of Medicine at Mount Sinai and New York City Health + Hospitals\/Elmhurst"},{"author_name":"Carson Woodbury","author_inst":"Icahn School of Medicine at Mount Sinai and New York City Health + Hospitals\/Elmhurst"},{"author_name":"Duncan Maru","author_inst":"Icahn School of Medicine at Mount Sinai and New York City Health + Hospitals\/Elmhurst"},{"author_name":"Lawrence Noble","author_inst":"Icahn School of Medicine at Mount Sinai and New York City Health + Hospitals\/Elmhurst"},{"author_name":"Randi Wasserman","author_inst":"Icahn School of Medicine at Mount Sinai and New York City Health + Hospitals\/Elmhurst"},{"author_name":"Barry Brown","author_inst":"Icahn School of Medicine at Mount Sinai and New York City Health + Hospitals\/Elmhurst"},{"author_name":"Rachel Vreeman","author_inst":"Icahn School of Medicine at Mount Sinai"},{"author_name":"Joseph Masci","author_inst":"Icahn School of Medicine at Mount Sinai and New York City Health + Hospitals\/Elmhurst"},{"author_name":"Nick A Maskell","author_inst":"Academic Respiratory Unit, North Bristol NHS Trust, Bristol, UK"},{"author_name":"Shaney Barratt","author_inst":"Academic Respiratory Unit, North Bristol NHS Trust, Bristol, UK"},{"author_name":"Carlos Sanchez-Garibay","author_inst":"Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez (INNyN), Mexico City, Mexico"},{"author_name":"Gabriela Hernandez-Molina","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Criselda Mendoza-Milla","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Andrea Dominguez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Julio Granados","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Lula Mena-Hernandez","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Luis Angel Perez-Buenfil","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Guillermo Dominguez-Cheritt","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Carlos Cabello-Gutierrez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Cesar Luna-Rivero","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Jorge Salas-Hernandez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Patricio Santilla-Doherty","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Justino Regalado","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Angelica Hernandez-Martinez","author_inst":"Instituto Nacional de Medicina Genomica, Mexico City, Mexico"},{"author_name":"Lorena Orozco","author_inst":"Instituto Nacional de Medicina Genomica, Mexico City, Mexico"},{"author_name":"Ethel A. Garcia-Latorre","author_inst":"Escuela Nacional de Ciencias Biologicas, Instituto Politecnico Nacional, Mexico City, Mexico"},{"author_name":"Carmen M. Hernandez-Cardenas","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Shabaana A. Khader","author_inst":"Department of Molecular Microbiology, Washington University School of Medicine in St Louis, MO, United States"},{"author_name":"Albert Zlotnik","author_inst":"Department of Physiology & Biophysics School of Medicine, Institute for Immunology, University of California, Irvine, United-States"},{"author_name":"Joaquin Zuniga","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"}],"version":"1","license":"cc_by_nc_nd","type":"PUBLISHAHEADOFPRINT","category":"health systems and quality improvement"},{"rel_doi":"10.1101\/2020.08.12.20173690","rel_title":"Antibody prevalence for SARS-CoV-2 in England following first peak of the pandemic: REACT2 study in 100,000 adults","rel_date":"2020-08-14","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.12.20173690","rel_abs":"Background England, UK has experienced a large outbreak of SARS-CoV-2 infection. As in USA and elsewhere, disadvantaged communities have been disproportionately affected. Methods National REal-time Assessment of Community Transmission-2 (REACT-2) seroprevalence study using self-administered lateral flow immunoassay (LFIA) test for IgG among a random population sample of 100,000 adults over 18 years in England, 20 June to 13 July 2020. Results Completed questionnaires were available for 109,076 participants, yielding 5,544 IgG positive results and adjusted (for test performance), re-weighted (for sampling) prevalence of 6.0% (95% CI: 5.8, 6.1). Highest prevalence was in London (13.0% [12.3, 13.6]), among people of Black or Asian (mainly South Asian) ethnicity (17.3% [15.8, 19.1] and 11.9% [11.0, 12.8] respectively) and those aged 18-24 years (7.9% [7.3, 8.5]). Care home workers with client-facing roles had adjusted odds ratio of 3.1 (2.5, 3.8) compared with non-essential workers. One third (32.2%, [31.0-33.4]) of antibody positive individuals reported no symptoms. Among symptomatic cases, the majority (78.8%) reported symptoms during the peak of the epidemic in England in March (31.3%) and April (47.5%) 2020. We estimate that 3.36 million (3.21, 3.51) people have been infected with SARS-CoV-2 in England to end June 2020, with an overall infection fatality ratio of 0.90% (0.86, 0.94). Conclusion The pandemic of SARS-CoV-2 infection in England disproportionately affected ethnic minority groups and health and care home workers. The higher risk of infection in these groups may explain, at least in part, their increased risk of hospitalisation and mortality from COVID-19.","rel_num_authors":14,"rel_authors":[{"author_name":"Helen Ward","author_inst":"Imperial College London"},{"author_name":"Christina J Atchison","author_inst":"Imperial College London"},{"author_name":"Matthew Whitaker","author_inst":"Imperial College London"},{"author_name":"Kylie E. C. Ainslie","author_inst":"Imperial College London"},{"author_name":"Joshua Elliott","author_inst":"Imperial College London"},{"author_name":"Lucy C Okell","author_inst":"Imperial College London"},{"author_name":"Rozlyn Redd","author_inst":"Imperial College London"},{"author_name":"Deborah Ashby","author_inst":"Imperial College London"},{"author_name":"Christl A. Donnelly","author_inst":"Imperial College London"},{"author_name":"Wendy Barclay","author_inst":"Imperial College London"},{"author_name":"Ara Darzi","author_inst":"Imperial College London"},{"author_name":"Graham Cooke","author_inst":"Imperial College London"},{"author_name":"Steven Riley","author_inst":"Dept Inf Dis Epi, Imperial College"},{"author_name":"Paul Elliott","author_inst":"Imperial College London"},{"author_name":"Rachel Vreeman","author_inst":"Icahn School of Medicine at Mount Sinai"},{"author_name":"Joseph Masci","author_inst":"Icahn School of Medicine at Mount Sinai and New York City Health + Hospitals\/Elmhurst"},{"author_name":"Nick A Maskell","author_inst":"Academic Respiratory Unit, North Bristol NHS Trust, Bristol, UK"},{"author_name":"Shaney Barratt","author_inst":"Academic Respiratory Unit, North Bristol NHS Trust, Bristol, UK"},{"author_name":"Carlos Sanchez-Garibay","author_inst":"Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez (INNyN), Mexico City, Mexico"},{"author_name":"Gabriela Hernandez-Molina","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Criselda Mendoza-Milla","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Andrea Dominguez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Julio Granados","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Lula Mena-Hernandez","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Luis Angel Perez-Buenfil","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Guillermo Dominguez-Cheritt","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Carlos Cabello-Gutierrez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Cesar Luna-Rivero","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Jorge Salas-Hernandez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Patricio Santilla-Doherty","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Justino Regalado","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Angelica Hernandez-Martinez","author_inst":"Instituto Nacional de Medicina Genomica, Mexico City, Mexico"},{"author_name":"Lorena Orozco","author_inst":"Instituto Nacional de Medicina Genomica, Mexico City, Mexico"},{"author_name":"Ethel A. Garcia-Latorre","author_inst":"Escuela Nacional de Ciencias Biologicas, Instituto Politecnico Nacional, Mexico City, Mexico"},{"author_name":"Carmen M. Hernandez-Cardenas","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Shabaana A. Khader","author_inst":"Department of Molecular Microbiology, Washington University School of Medicine in St Louis, MO, United States"},{"author_name":"Albert Zlotnik","author_inst":"Department of Physiology & Biophysics School of Medicine, Institute for Immunology, University of California, Irvine, United-States"},{"author_name":"Joaquin Zuniga","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"}],"version":"1","license":"cc_by_nc_nd","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.08.13.20174060","rel_title":"Comprehensive Systematic Review to Identify putative COVID-19 Treatments: Roles for Immunomodulator and Antiviral Treatments","rel_date":"2020-08-14","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.13.20174060","rel_abs":"Objectives: To identify putative COVID-19 treatments and identify the roles of immunomodulators and antivirals in disease management. Design: Systematic review. Data sources: PubMed, bioRxiv.org and medRxiv.org were searched for studies suggestive of effective treatments for COVID-19. Additional studies were identified via a snowballing method applied to the references of retrieved papers as well as a subsequent targeted search for drug names. Review methods: Inclusion criteria included any case series or randomised control trials in any language that were published from 18th December 2019 to 18th April 2020 and described COVID-19 treatment. Of an initial 2140 studies identified from the initial search, 29 studies were found to meet the inclusion criteria and included in this comprehensive systematic review. Results: 19 studies of antiviral treatments for COVID-19 have been reported and seven studies for immunomodulatory treatments. Six randomised controlled trials have been published with one positive trial for Hydroxychloroquine. This small study consisted of 31 patients though subsequent studies showed contradictory findings. All the remaining studies were observational studies, retrospective case reviews or non-randomised trials and these results are difficult to interpret due to methodological issues. Conclusions: To date, an impressive number of studies have been performed in a short space of time, indicative of a resilient clinical trials infrastructure. However, there is a lack of high quality evidence to support any novel treatments for COVID-19 to be incorporated into the current standard of care. The majority of the studies of treatments for COVID-19 could only be found in pre-print servers. Future clinical reviews should therefore be Comprehensive Systematic Reviews involving pre-print studies to prevent potential unnecessary replications of clinical studies.","rel_num_authors":4,"rel_authors":[{"author_name":"Thomas Hill","author_inst":"Department of Oncology, Queen Elizabeth Hospital Birmingham, Mindelsohn Way, Edgbaston, B152GW"},{"author_name":"Mark Baker","author_inst":"Birmingham Medical School, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT"},{"author_name":"Lawrence Isherwood","author_inst":"Birmingham Medical School, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT"},{"author_name":"Lennard YW Lee","author_inst":"Department of Oncology, Queen Elizabeth Hospital Birmingham, Mindelsohn Way, Edgbaston B15 2GW, United Kingdom. Institute of Cancer and Genomic Sciences, Univer"},{"author_name":"Joshua Elliott","author_inst":"Imperial College London"},{"author_name":"Lucy C Okell","author_inst":"Imperial College London"},{"author_name":"Rozlyn Redd","author_inst":"Imperial College London"},{"author_name":"Deborah Ashby","author_inst":"Imperial College London"},{"author_name":"Christl A. Donnelly","author_inst":"Imperial College London"},{"author_name":"Wendy Barclay","author_inst":"Imperial College London"},{"author_name":"Ara Darzi","author_inst":"Imperial College London"},{"author_name":"Graham Cooke","author_inst":"Imperial College London"},{"author_name":"Steven Riley","author_inst":"Dept Inf Dis Epi, Imperial College"},{"author_name":"Paul Elliott","author_inst":"Imperial College London"},{"author_name":"Rachel Vreeman","author_inst":"Icahn School of Medicine at Mount Sinai"},{"author_name":"Joseph Masci","author_inst":"Icahn School of Medicine at Mount Sinai and New York City Health + Hospitals\/Elmhurst"},{"author_name":"Nick A Maskell","author_inst":"Academic Respiratory Unit, North Bristol NHS Trust, Bristol, UK"},{"author_name":"Shaney Barratt","author_inst":"Academic Respiratory Unit, North Bristol NHS Trust, Bristol, UK"},{"author_name":"Carlos Sanchez-Garibay","author_inst":"Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez (INNyN), Mexico City, Mexico"},{"author_name":"Gabriela Hernandez-Molina","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Criselda Mendoza-Milla","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Andrea Dominguez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Julio Granados","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Lula Mena-Hernandez","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Luis Angel Perez-Buenfil","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Guillermo Dominguez-Cheritt","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Carlos Cabello-Gutierrez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Cesar Luna-Rivero","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Jorge Salas-Hernandez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Patricio Santilla-Doherty","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Justino Regalado","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Angelica Hernandez-Martinez","author_inst":"Instituto Nacional de Medicina Genomica, Mexico City, Mexico"},{"author_name":"Lorena Orozco","author_inst":"Instituto Nacional de Medicina Genomica, Mexico City, Mexico"},{"author_name":"Ethel A. Garcia-Latorre","author_inst":"Escuela Nacional de Ciencias Biologicas, Instituto Politecnico Nacional, Mexico City, Mexico"},{"author_name":"Carmen M. Hernandez-Cardenas","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Shabaana A. Khader","author_inst":"Department of Molecular Microbiology, Washington University School of Medicine in St Louis, MO, United States"},{"author_name":"Albert Zlotnik","author_inst":"Department of Physiology & Biophysics School of Medicine, Institute for Immunology, University of California, Irvine, United-States"},{"author_name":"Joaquin Zuniga","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"}],"version":"1","license":"cc0_ng","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.08.12.20173104","rel_title":"First report of tocilizumab use in a cohort of Latin American patients hospitalized for severe COVID-19 pneumonia","rel_date":"2020-08-14","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.12.20173104","rel_abs":"Introduction\/objectives: An interleukin-6 inhibition strategy could be effective in selected COVID-19 patients. The objective is to present our experience of tocilizumab use in patients with severe COVID-19. Methods: Observational retrospective cohort study. Hospitalized patients were evaluated by our multidisciplinary team for eventual use of tocilizumab. Patients with progressive ventilatory impairment and evidence of a hyperinflammatory state despite usual treatment received tocilizumab 8 mg\/kg intravenous (maximum dose 800 mg), in addition to standard treatment. The use and time of use of mechanical ventilation (MV), the change of the Alveolar-arterial (A-a) gradient, of the ratio of arterial oxygen partial pressure to fractional inspired oxygen (PaO2\/FiO2) and of inflammation laboratory parameters after 72 hours of tocilizumab use was evaluated. Results: 29 patients received tocilizumab. 93.1% were men, 37.9% were obese, and 34.5% had hypertension. Of the 20 patients who were not on MV when receiving tocilizumab, 11 required non-invasive MV, for an average of five days, and one of them required intubation. A-a gradient, PaO2\/FiO2, and inflammation parameters improved significantly. A better lymphocyte count, which improved significantly after tocilizumab use, was significantly associated with less use of MV. Five patients presented positive culture samples after tocilizumab, three being of clinical significance. A lower lymphocyte count was associated with having a positive culture. No other significant adverse events were seen. Conclusion: Our study suggests the utility and shows the safety of tocilizumab use in COVID-19 patients who have respiratory failure and evidence of hyperinflammation. Lymphocyte improvement was a predictor of good response.","rel_num_authors":11,"rel_authors":[{"author_name":"Omar Valenzuela","author_inst":"Clinica Alemana de Santiago"},{"author_name":"Sebastian E Ibanez","author_inst":"Clinica Alemana de Santiago"},{"author_name":"Maria Poli","author_inst":"Clinica Alemana de Santiago"},{"author_name":"Patricia Roessler","author_inst":"Clinica Alemana de Santiago"},{"author_name":"Mabel Aylwin","author_inst":"Clinica Alemana de Santiago"},{"author_name":"Gigia Roizen","author_inst":"Clinica Alemana de Santiago"},{"author_name":"Mirentxu Iruretagoyena","author_inst":"Clinica Alemana de Santiago"},{"author_name":"Vivianne Agar","author_inst":"Clinica Alemana de Santiago"},{"author_name":"Javiera Donoso","author_inst":"Clinica Alemana de Santiago"},{"author_name":"Margarita Fierro","author_inst":"Clinica Alemana de Santiago"},{"author_name":"Jose Montes","author_inst":"Clinica Alemana de Santiago"},{"author_name":"Graham Cooke","author_inst":"Imperial College London"},{"author_name":"Steven Riley","author_inst":"Dept Inf Dis Epi, Imperial College"},{"author_name":"Paul Elliott","author_inst":"Imperial College London"},{"author_name":"Rachel Vreeman","author_inst":"Icahn School of Medicine at Mount Sinai"},{"author_name":"Joseph Masci","author_inst":"Icahn School of Medicine at Mount Sinai and New York City Health + Hospitals\/Elmhurst"},{"author_name":"Nick A Maskell","author_inst":"Academic Respiratory Unit, North Bristol NHS Trust, Bristol, UK"},{"author_name":"Shaney Barratt","author_inst":"Academic Respiratory Unit, North Bristol NHS Trust, Bristol, UK"},{"author_name":"Carlos Sanchez-Garibay","author_inst":"Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez (INNyN), Mexico City, Mexico"},{"author_name":"Gabriela Hernandez-Molina","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Criselda Mendoza-Milla","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Andrea Dominguez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Julio Granados","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Lula Mena-Hernandez","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Luis Angel Perez-Buenfil","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Guillermo Dominguez-Cheritt","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Carlos Cabello-Gutierrez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Cesar Luna-Rivero","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Jorge Salas-Hernandez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Patricio Santilla-Doherty","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Justino Regalado","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Angelica Hernandez-Martinez","author_inst":"Instituto Nacional de Medicina Genomica, Mexico City, Mexico"},{"author_name":"Lorena Orozco","author_inst":"Instituto Nacional de Medicina Genomica, Mexico City, Mexico"},{"author_name":"Ethel A. Garcia-Latorre","author_inst":"Escuela Nacional de Ciencias Biologicas, Instituto Politecnico Nacional, Mexico City, Mexico"},{"author_name":"Carmen M. Hernandez-Cardenas","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Shabaana A. Khader","author_inst":"Department of Molecular Microbiology, Washington University School of Medicine in St Louis, MO, United States"},{"author_name":"Albert Zlotnik","author_inst":"Department of Physiology & Biophysics School of Medicine, Institute for Immunology, University of California, Irvine, United-States"},{"author_name":"Joaquin Zuniga","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"}],"version":"1","license":"cc_by_nc_nd","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.08.13.20173914","rel_title":"Sero-prevalence findings from metropoles in Pakistan: implications for assessing COVID-19 prevalence and case-fatality within a dense, urban working population","rel_date":"2020-08-14","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.13.20173914","rel_abs":"Population-level serologic testing has demonstrated groundbreaking results in monitoring the prevalence and case-fatality of COVID-19 within a population. In Pakistan, Getz Pharma conducted a sero-prevalence survey on a sample of 24,210 individuals using the IgG\/IgM Test Kit (Colloidal gold) with follow-up and sequential testing after every 15-20 days on a sub-sample. This is the first of its kind, large scale census conducted on a dense, urban, working population in Pakistan. The study results reveal that from 24,210 individuals screened, 17.5% tested positive, with 7% IgM positive, 6.0% IgG positive and 4.5% combined IgM and IgG positive. These findings have been extrapolated to the rest of the urban, adult, working population of Pakistan, and as of 6th July, 2020, 4.11 million people in Pakistan have been infected with COVID-19, which is 17.7 times higher than the current number of 231,818 symptom-based PCR cases reported by the government which exclude asymptomatic cases.","rel_num_authors":4,"rel_authors":[{"author_name":"Wajiha Javed","author_inst":"Getz Pharma"},{"author_name":"Jaffer Bin Baqar","author_inst":"Getz Pharma"},{"author_name":"Syed Hussain Baqar Abidi","author_inst":"Getz Pharma"},{"author_name":"Wajiha Farooq","author_inst":"Getz Pharma"},{"author_name":"Mabel Aylwin","author_inst":"Clinica Alemana de Santiago"},{"author_name":"Gigia Roizen","author_inst":"Clinica Alemana de Santiago"},{"author_name":"Mirentxu Iruretagoyena","author_inst":"Clinica Alemana de Santiago"},{"author_name":"Vivianne Agar","author_inst":"Clinica Alemana de Santiago"},{"author_name":"Javiera Donoso","author_inst":"Clinica Alemana de Santiago"},{"author_name":"Margarita Fierro","author_inst":"Clinica Alemana de Santiago"},{"author_name":"Jose Montes","author_inst":"Clinica Alemana de Santiago"},{"author_name":"Graham Cooke","author_inst":"Imperial College London"},{"author_name":"Steven Riley","author_inst":"Dept Inf Dis Epi, Imperial College"},{"author_name":"Paul Elliott","author_inst":"Imperial College London"},{"author_name":"Rachel Vreeman","author_inst":"Icahn School of Medicine at Mount Sinai"},{"author_name":"Joseph Masci","author_inst":"Icahn School of Medicine at Mount Sinai and New York City Health + Hospitals\/Elmhurst"},{"author_name":"Nick A Maskell","author_inst":"Academic Respiratory Unit, North Bristol NHS Trust, Bristol, UK"},{"author_name":"Shaney Barratt","author_inst":"Academic Respiratory Unit, North Bristol NHS Trust, Bristol, UK"},{"author_name":"Carlos Sanchez-Garibay","author_inst":"Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez (INNyN), Mexico City, Mexico"},{"author_name":"Gabriela Hernandez-Molina","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Criselda Mendoza-Milla","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Andrea Dominguez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Julio Granados","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Lula Mena-Hernandez","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Luis Angel Perez-Buenfil","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Guillermo Dominguez-Cheritt","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Carlos Cabello-Gutierrez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Cesar Luna-Rivero","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Jorge Salas-Hernandez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Patricio Santilla-Doherty","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Justino Regalado","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Angelica Hernandez-Martinez","author_inst":"Instituto Nacional de Medicina Genomica, Mexico City, Mexico"},{"author_name":"Lorena Orozco","author_inst":"Instituto Nacional de Medicina Genomica, Mexico City, Mexico"},{"author_name":"Ethel A. Garcia-Latorre","author_inst":"Escuela Nacional de Ciencias Biologicas, Instituto Politecnico Nacional, Mexico City, Mexico"},{"author_name":"Carmen M. Hernandez-Cardenas","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Shabaana A. Khader","author_inst":"Department of Molecular Microbiology, Washington University School of Medicine in St Louis, MO, United States"},{"author_name":"Albert Zlotnik","author_inst":"Department of Physiology & Biophysics School of Medicine, Institute for Immunology, University of California, Irvine, United-States"},{"author_name":"Joaquin Zuniga","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"}],"version":"1","license":"cc_no","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.08.12.20173617","rel_title":"Comprehensive analysis of the key epidemiological parameters to evaluate the impact of BCG vaccination on COVID-19 pandemic","rel_date":"2020-08-14","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.12.20173617","rel_abs":"Globally, the heterogenous coronavirus disease 2019 (COVID-19) case fatality rate (CFR) could be influenced by various epidemiological parameters. Identifying these could help formulate effective public health strategies. Incidence and mortality of COVID-19 for each of the 220 countries as on July 30, 2020 were evaluated against key epidemiological variables, namely - BCG vaccination (ongoing vs. discontinued\/never undertaken), %population aged [&ge;]65 years, incidences of ischemic heart disease (IHD), hypertensive heart disease (HHD), cancer, malaria, and diabetes; human development index (HDI) and population density. These were retrieved from the public domains of WHO, UN, World Bank and published reports. The COVID-19 CFRs ranged between 0.0% and 28.3% (mean {+\/-} SD: 3.05% {+\/-} 3.48). The influence of the individual epidemiological parameters on CFR were evaluated through the event rate estimations. A significantly lower event rate was observed in countries with ongoing BCG vaccination program (ER: with vs without ongoing BCG vaccination: 0.020 vs 0.034, p<0.001). The type of BCG strains used also influenced the ER; this being 0.018, 0.031 and 0.019 for early, late and mixed strains respectively (p=0.008). The epidemiological variables significantly associated with higher COVID-19 event rate were countries with higher %population aged [&ge;]65 years (p<0.001), greater incidence of IHD (p<0.001) and cancer (p=0.003) and better HDI (p=0.003). Incidences of malaria, HHD and diabetes along with population density had no significant impact on COVID-19 CFR. Further, BCG vaccination significantly lowered the COVID-19 ER in each of the high-risk population subgroups - countries with >7.1% population aged [&ge;]65 years (p=0.008), >0.737 HDI (p=0.001), IHD >1171\/105 population (p=0.004) and cancer incidence >15726 (p<0.001). The results supports BCG induced trained immunity leading to heterologous immunoprotection against COVID-19. Thus BCG vaccination with early strains could provide a cost-effective prophylaxis, especially in high-risk individuals and bridge the gap till an effective vaccine against SARS-CoV-2 is freely available globally.","rel_num_authors":2,"rel_authors":[{"author_name":"Niloy R Datta","author_inst":"Kantonsspital Aarau"},{"author_name":"Sneha Datta","author_inst":"Independent Researcher"},{"author_name":"Syed Hussain Baqar Abidi","author_inst":"Getz Pharma"},{"author_name":"Wajiha Farooq","author_inst":"Getz Pharma"},{"author_name":"Mabel Aylwin","author_inst":"Clinica Alemana de Santiago"},{"author_name":"Gigia Roizen","author_inst":"Clinica Alemana de Santiago"},{"author_name":"Mirentxu Iruretagoyena","author_inst":"Clinica Alemana de Santiago"},{"author_name":"Vivianne Agar","author_inst":"Clinica Alemana de Santiago"},{"author_name":"Javiera Donoso","author_inst":"Clinica Alemana de Santiago"},{"author_name":"Margarita Fierro","author_inst":"Clinica Alemana de Santiago"},{"author_name":"Jose Montes","author_inst":"Clinica Alemana de Santiago"},{"author_name":"Graham Cooke","author_inst":"Imperial College London"},{"author_name":"Steven Riley","author_inst":"Dept Inf Dis Epi, Imperial College"},{"author_name":"Paul Elliott","author_inst":"Imperial College London"},{"author_name":"Rachel Vreeman","author_inst":"Icahn School of Medicine at Mount Sinai"},{"author_name":"Joseph Masci","author_inst":"Icahn School of Medicine at Mount Sinai and New York City Health + Hospitals\/Elmhurst"},{"author_name":"Nick A Maskell","author_inst":"Academic Respiratory Unit, North Bristol NHS Trust, Bristol, UK"},{"author_name":"Shaney Barratt","author_inst":"Academic Respiratory Unit, North Bristol NHS Trust, Bristol, UK"},{"author_name":"Carlos Sanchez-Garibay","author_inst":"Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez (INNyN), Mexico City, Mexico"},{"author_name":"Gabriela Hernandez-Molina","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Criselda Mendoza-Milla","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Andrea Dominguez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Julio Granados","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Lula Mena-Hernandez","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Luis Angel Perez-Buenfil","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Guillermo Dominguez-Cheritt","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Carlos Cabello-Gutierrez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Cesar Luna-Rivero","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Jorge Salas-Hernandez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Patricio Santilla-Doherty","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Justino Regalado","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Angelica Hernandez-Martinez","author_inst":"Instituto Nacional de Medicina Genomica, Mexico City, Mexico"},{"author_name":"Lorena Orozco","author_inst":"Instituto Nacional de Medicina Genomica, Mexico City, Mexico"},{"author_name":"Ethel A. Garcia-Latorre","author_inst":"Escuela Nacional de Ciencias Biologicas, Instituto Politecnico Nacional, Mexico City, Mexico"},{"author_name":"Carmen M. Hernandez-Cardenas","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Shabaana A. Khader","author_inst":"Department of Molecular Microbiology, Washington University School of Medicine in St Louis, MO, United States"},{"author_name":"Albert Zlotnik","author_inst":"Department of Physiology & Biophysics School of Medicine, Institute for Immunology, University of California, Irvine, United-States"},{"author_name":"Joaquin Zuniga","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"}],"version":"1","license":"cc_no","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.08.12.20173849","rel_title":"Obesity and Smoking as Risk Factors for Invasive Mechanical Ventilation in COVID-19: a Retrospective, Observational Cohort Study","rel_date":"2020-08-14","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.12.20173849","rel_abs":"Purpose: To describe the trajectory of respiratory failure in COVID-19 and explore factors associated with risk of invasive mechanical ventilation (IMV). Materials and Methods: A retrospective, observational cohort study of 112 inpatient adults diagnosed with COVID-19 between March 12 and April 16, 2020. Data were manually extracted from electronic medical records. Multivariable and Univariable regression were used to evaluate association between baseline characteristics, initial serum markers and the outcome of IMV. Results: Our cohort had median age of 61 (IQR 45-74) and was 66% male. In-hospital mortality was 6% (7\/112). ICU mortality was 12.8% (6\/47), and 18% (5\/28) for those requiring IMV. Obesity (OR 5.82, CI 1.74-19.48), former (OR 8.06, CI 1.51-43.06) and current smoking status (OR 10.33, CI 1.43-74.67) were associated with IMV after adjusting for age, sex, and high prevalence comorbidities by multivariable analysis. Initial absolute lymphocyte count (OR 0.33, CI 0.11-0.96), procalcitonin (OR 1.27, CI 1.02-1.57), IL-6 (OR 1.17, CI 1.03-1.33), ferritin (OR 1.05, CI 1.005-1.11), LDH (OR 1.57, 95% CI 1.13-2.17) and CRP (OR 1.13, CI 1.06-1.21), were associated with IMV by univariate analysis. Conclusions: Obesity, smoking history, and elevated inflammatory markers were associated with increased need for IMV in patients with COVID-19.","rel_num_authors":14,"rel_authors":[{"author_name":"Ana Carolina Costa Monteiro","author_inst":"UCLA Ronald Reagan"},{"author_name":"Rajat Suri","author_inst":"UCLA Ronald Reagan"},{"author_name":"Ileanacho Obi Emeruwa","author_inst":"UCLA Ronald Reagan"},{"author_name":"Robert J Stretch","author_inst":"UCLA Ronald Reagan"},{"author_name":"Roxana Y Cortes Lopez","author_inst":"UCLA Ronald Reagan"},{"author_name":"Alexander Sherman","author_inst":"UCLA Ronald Reagan"},{"author_name":"Catherine C Lindsay","author_inst":"UCLA Ronald Reagan"},{"author_name":"Jennifer A Fulcher","author_inst":"UCLA Ronald Reagan"},{"author_name":"David Goodman-Meza","author_inst":"UCLA Ronald Reagan"},{"author_name":"Anil Sapru","author_inst":"UCLA Ronald Reagan"},{"author_name":"Russell G Buhr","author_inst":"UCLA Ronald Reagan"},{"author_name":"Steven Y Chang","author_inst":"UCLA Ronald Reagan"},{"author_name":"Tisha Wang","author_inst":"UCLA Ronald Reagan"},{"author_name":"Nida Qadir","author_inst":"UCLA Ronald Reagan"},{"author_name":"Rachel Vreeman","author_inst":"Icahn School of Medicine at Mount Sinai"},{"author_name":"Joseph Masci","author_inst":"Icahn School of Medicine at Mount Sinai and New York City Health + Hospitals\/Elmhurst"},{"author_name":"Nick A Maskell","author_inst":"Academic Respiratory Unit, North Bristol NHS Trust, Bristol, UK"},{"author_name":"Shaney Barratt","author_inst":"Academic Respiratory Unit, North Bristol NHS Trust, Bristol, UK"},{"author_name":"Carlos Sanchez-Garibay","author_inst":"Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez (INNyN), Mexico City, Mexico"},{"author_name":"Gabriela Hernandez-Molina","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Criselda Mendoza-Milla","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Andrea Dominguez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Julio Granados","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Lula Mena-Hernandez","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Luis Angel Perez-Buenfil","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Guillermo Dominguez-Cheritt","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Carlos Cabello-Gutierrez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Cesar Luna-Rivero","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Jorge Salas-Hernandez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Patricio Santilla-Doherty","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Justino Regalado","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Angelica Hernandez-Martinez","author_inst":"Instituto Nacional de Medicina Genomica, Mexico City, Mexico"},{"author_name":"Lorena Orozco","author_inst":"Instituto Nacional de Medicina Genomica, Mexico City, Mexico"},{"author_name":"Ethel A. Garcia-Latorre","author_inst":"Escuela Nacional de Ciencias Biologicas, Instituto Politecnico Nacional, Mexico City, Mexico"},{"author_name":"Carmen M. Hernandez-Cardenas","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Shabaana A. Khader","author_inst":"Department of Molecular Microbiology, Washington University School of Medicine in St Louis, MO, United States"},{"author_name":"Albert Zlotnik","author_inst":"Department of Physiology & Biophysics School of Medicine, Institute for Immunology, University of California, Irvine, United-States"},{"author_name":"Joaquin Zuniga","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"}],"version":"1","license":"cc_by_nc_nd","type":"PUBLISHAHEADOFPRINT","category":"intensive care and critical care medicine"},{"rel_doi":"10.1101\/2020.08.12.20173450","rel_title":"Analysing air particle quantity in a dental primary care setting","rel_date":"2020-08-14","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.12.20173450","rel_abs":"Objectives: This study was undertaken to assess the amount of dental aerosol created in a primary care dental surgery. Methods: Two particle meters were placed a set distances round a volunteer patient whilst undergoing simulated dental treatment using a high speed dental handpiece, and 3-in-1 air\/water syringe, moisture control was managed with high volume suction and a saliva ejector. Measurement were taken every thirty seconds with the surgery environment set a neutral ventilation and with the windows open plus fan assistance. Results: From the cessation of aerosol generation it took between 6 and 19 minutes for the surgery to return to baseline. The ventilated surgery had faster aerosol dispersal, returning to background levels within 5 minutes. Conclusion: It is concluded for the surgery under investigation the dental aerosol had dissipated after 30 minutes using HVS and optimal surgery.","rel_num_authors":2,"rel_authors":[{"author_name":"Daniel Bates","author_inst":"Loughborough University"},{"author_name":"Andrew Bates","author_inst":"Gargrave Road Dental Practice"},{"author_name":"Ileanacho Obi Emeruwa","author_inst":"UCLA Ronald Reagan"},{"author_name":"Robert J Stretch","author_inst":"UCLA Ronald Reagan"},{"author_name":"Roxana Y Cortes Lopez","author_inst":"UCLA Ronald Reagan"},{"author_name":"Alexander Sherman","author_inst":"UCLA Ronald Reagan"},{"author_name":"Catherine C Lindsay","author_inst":"UCLA Ronald Reagan"},{"author_name":"Jennifer A Fulcher","author_inst":"UCLA Ronald Reagan"},{"author_name":"David Goodman-Meza","author_inst":"UCLA Ronald Reagan"},{"author_name":"Anil Sapru","author_inst":"UCLA Ronald Reagan"},{"author_name":"Russell G Buhr","author_inst":"UCLA Ronald Reagan"},{"author_name":"Steven Y Chang","author_inst":"UCLA Ronald Reagan"},{"author_name":"Tisha Wang","author_inst":"UCLA Ronald Reagan"},{"author_name":"Nida Qadir","author_inst":"UCLA Ronald Reagan"},{"author_name":"Rachel Vreeman","author_inst":"Icahn School of Medicine at Mount Sinai"},{"author_name":"Joseph Masci","author_inst":"Icahn School of Medicine at Mount Sinai and New York City Health + Hospitals\/Elmhurst"},{"author_name":"Nick A Maskell","author_inst":"Academic Respiratory Unit, North Bristol NHS Trust, Bristol, UK"},{"author_name":"Shaney Barratt","author_inst":"Academic Respiratory Unit, North Bristol NHS Trust, Bristol, UK"},{"author_name":"Carlos Sanchez-Garibay","author_inst":"Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez (INNyN), Mexico City, Mexico"},{"author_name":"Gabriela Hernandez-Molina","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Criselda Mendoza-Milla","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Andrea Dominguez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Julio Granados","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Lula Mena-Hernandez","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Luis Angel Perez-Buenfil","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Guillermo Dominguez-Cheritt","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Carlos Cabello-Gutierrez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Cesar Luna-Rivero","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Jorge Salas-Hernandez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Patricio Santilla-Doherty","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Justino Regalado","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Angelica Hernandez-Martinez","author_inst":"Instituto Nacional de Medicina Genomica, Mexico City, Mexico"},{"author_name":"Lorena Orozco","author_inst":"Instituto Nacional de Medicina Genomica, Mexico City, Mexico"},{"author_name":"Ethel A. Garcia-Latorre","author_inst":"Escuela Nacional de Ciencias Biologicas, Instituto Politecnico Nacional, Mexico City, Mexico"},{"author_name":"Carmen M. Hernandez-Cardenas","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Shabaana A. Khader","author_inst":"Department of Molecular Microbiology, Washington University School of Medicine in St Louis, MO, United States"},{"author_name":"Albert Zlotnik","author_inst":"Department of Physiology & Biophysics School of Medicine, Institute for Immunology, University of California, Irvine, United-States"},{"author_name":"Joaquin Zuniga","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"}],"version":"1","license":"cc_by","type":"PUBLISHAHEADOFPRINT","category":"dentistry and oral medicine"},{"rel_doi":"10.1101\/2020.08.11.20173039","rel_title":"Local protection bubbles: an interpretation of the decrease in the velocity of coronavirus's spread in the city of Sao Paulo","rel_date":"2020-08-14","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.11.20173039","rel_abs":"After four months of dealing with the pandemic, the city of Sao Paulo entered a phase of relaxed social-distancing measures in July 2020, and saw its social isolation rate fall at the same time as the number of cases, deaths, and hospital bed occupation declined. We use a calibrated multi-agent model to describe these dynamics. We assert here that this phenomenon can be understood as the result of local protective bubbles formed in the city's sub-environments at the same time that there was an exhaustion of contagion networks. Both reduce the velocity of the virus's spread, causing temporary reductions in the epidemic curve, albeit in an unstable equilibrium. These local bubbles can burst anytime and anywhere due to the reintroduction of a few infected people at the same time that there is a reduction in non-pharmaceutical interventions (NPI), such as social-distancing practices. It is important to stress that this hypothesis aligns with the dynamics of the virus's spread observed so far, without needing ad hoc suppositions about natural collective immunity thresholds or heterogeneity in the population's transmission rate, which come with the risk of making mistaken predictions that may could lead to the loss of many lives. The safe way to move ahead is to continue doing all we can to avoid new infections until a vaccine is found that properly and safely creates herd immunity.","rel_num_authors":5,"rel_authors":[{"author_name":"Jose Paulo Guedes Pinto","author_inst":"Federal University of ABC (UFABC)"},{"author_name":"Patricia Camargo Magalhaes","author_inst":"University of Bristol"},{"author_name":"Gerusa Maria Figueiredo","author_inst":"University of Sao Paulo"},{"author_name":"Domingos Alves","author_inst":"University of Sao Paulo"},{"author_name":"Diana Maritza Segura-Angel","author_inst":"Army Aviation School, Bogota, Colombia"},{"author_name":"Alexander Sherman","author_inst":"UCLA Ronald Reagan"},{"author_name":"Catherine C Lindsay","author_inst":"UCLA Ronald Reagan"},{"author_name":"Jennifer A Fulcher","author_inst":"UCLA Ronald Reagan"},{"author_name":"David Goodman-Meza","author_inst":"UCLA Ronald Reagan"},{"author_name":"Anil Sapru","author_inst":"UCLA Ronald Reagan"},{"author_name":"Russell G Buhr","author_inst":"UCLA Ronald Reagan"},{"author_name":"Steven Y Chang","author_inst":"UCLA Ronald Reagan"},{"author_name":"Tisha Wang","author_inst":"UCLA Ronald Reagan"},{"author_name":"Nida Qadir","author_inst":"UCLA Ronald Reagan"},{"author_name":"Rachel Vreeman","author_inst":"Icahn School of Medicine at Mount Sinai"},{"author_name":"Joseph Masci","author_inst":"Icahn School of Medicine at Mount Sinai and New York City Health + Hospitals\/Elmhurst"},{"author_name":"Nick A Maskell","author_inst":"Academic Respiratory Unit, North Bristol NHS Trust, Bristol, UK"},{"author_name":"Shaney Barratt","author_inst":"Academic Respiratory Unit, North Bristol NHS Trust, Bristol, UK"},{"author_name":"Carlos Sanchez-Garibay","author_inst":"Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez (INNyN), Mexico City, Mexico"},{"author_name":"Gabriela Hernandez-Molina","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Criselda Mendoza-Milla","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Andrea Dominguez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Julio Granados","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Lula Mena-Hernandez","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Luis Angel Perez-Buenfil","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Guillermo Dominguez-Cheritt","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Carlos Cabello-Gutierrez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Cesar Luna-Rivero","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Jorge Salas-Hernandez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Patricio Santilla-Doherty","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Justino Regalado","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Angelica Hernandez-Martinez","author_inst":"Instituto Nacional de Medicina Genomica, Mexico City, Mexico"},{"author_name":"Lorena Orozco","author_inst":"Instituto Nacional de Medicina Genomica, Mexico City, Mexico"},{"author_name":"Ethel A. Garcia-Latorre","author_inst":"Escuela Nacional de Ciencias Biologicas, Instituto Politecnico Nacional, Mexico City, Mexico"},{"author_name":"Carmen M. Hernandez-Cardenas","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Shabaana A. Khader","author_inst":"Department of Molecular Microbiology, Washington University School of Medicine in St Louis, MO, United States"},{"author_name":"Albert Zlotnik","author_inst":"Department of Physiology & Biophysics School of Medicine, Institute for Immunology, University of California, Irvine, United-States"},{"author_name":"Joaquin Zuniga","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"}],"version":"1","license":"cc_by_nc","type":"PUBLISHAHEADOFPRINT","category":"epidemiology"},{"rel_doi":"10.1101\/2020.08.13.20163030","rel_title":"Clinical characteristics and Outcomes of 500 patients with COVID Pneumonia : Results from a Single center(Southend University Hospital)","rel_date":"2020-08-14","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.13.20163030","rel_abs":"Objectives To characterise the clinical features of hospitalised COVID 19 patients in a single centre during the first epidemic wave and explore potential predictive variables associated with outcomes such as mortality and the need for mechanical ventilation, using baseline clinical parameters. Methodology We conducted a retrospective review of electronic records for demographic, clinical and laboratory data, imaging and outcomes for 500 hospitalised patients between February 20th and May 7th 2020 from Southend University Hospital, Essex, UK. Multivariate logistic regression models were used to identify risk factors relevant to outcome. Results The mean age of the cohort admitted to hospital with Covid-19, was 69.4 and 290 (58%) were over 70. The majority were Caucasians, 437 (87%) with less than 2 co-morbidities 280(56%). Most common were hypertension 186(37 %), Cardiovascular disease 178(36 %) and Diabetes 128 (26 %), represented in a larger proportion on the mortality group. Mean CFS was 4 with Non Survivors had significantly higher CFS 5 vs 3 in survivors, p<0.001. In addition, Mean CRP was significantly higher 150 vs 90, p<0.001 in Non Survivors. We observed the baseline predictors for mortality were age, CFS and CRP. Conclusions In this single centre study, older and frailer patients with more comorbidities and a higher baseline CRP and creatinine were risk factors for worse outcomes. Integrated frailty and age based risk stratification are essential, in addition to monitoring SFR (Sp02\/Fi02) and inflammatory markers throughout the disease course to allow for early intervention to improve patient outcomes.","rel_num_authors":8,"rel_authors":[{"author_name":"Gouri Koduri","author_inst":"Southend University Hospital"},{"author_name":"Sriya Gokaraju","author_inst":"Southend University Hospital"},{"author_name":"Maria Darda","author_inst":"Southend University Hospital"},{"author_name":"Vinod Warrier","author_inst":"Southend University Hospital"},{"author_name":"Irina Duta","author_inst":"Southend University Hospital"},{"author_name":"Fiona Hayes","author_inst":"Southend University Hospital"},{"author_name":"Iman El Sayed","author_inst":"Alexandria University, EG"},{"author_name":"Yasser Noeman Ahmed","author_inst":"Southend University Hospital"},{"author_name":"David Goodman-Meza","author_inst":"UCLA Ronald Reagan"},{"author_name":"Anil Sapru","author_inst":"UCLA Ronald Reagan"},{"author_name":"Russell G Buhr","author_inst":"UCLA Ronald Reagan"},{"author_name":"Steven Y Chang","author_inst":"UCLA Ronald Reagan"},{"author_name":"Tisha Wang","author_inst":"UCLA Ronald Reagan"},{"author_name":"Nida Qadir","author_inst":"UCLA Ronald Reagan"},{"author_name":"Rachel Vreeman","author_inst":"Icahn School of Medicine at Mount Sinai"},{"author_name":"Joseph Masci","author_inst":"Icahn School of Medicine at Mount Sinai and New York City Health + Hospitals\/Elmhurst"},{"author_name":"Nick A Maskell","author_inst":"Academic Respiratory Unit, North Bristol NHS Trust, Bristol, UK"},{"author_name":"Shaney Barratt","author_inst":"Academic Respiratory Unit, North Bristol NHS Trust, Bristol, UK"},{"author_name":"Carlos Sanchez-Garibay","author_inst":"Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez (INNyN), Mexico City, Mexico"},{"author_name":"Gabriela Hernandez-Molina","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Criselda Mendoza-Milla","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Andrea Dominguez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Julio Granados","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Lula Mena-Hernandez","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Luis Angel Perez-Buenfil","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Guillermo Dominguez-Cheritt","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Carlos Cabello-Gutierrez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Cesar Luna-Rivero","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Jorge Salas-Hernandez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Patricio Santilla-Doherty","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Justino Regalado","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Angelica Hernandez-Martinez","author_inst":"Instituto Nacional de Medicina Genomica, Mexico City, Mexico"},{"author_name":"Lorena Orozco","author_inst":"Instituto Nacional de Medicina Genomica, Mexico City, Mexico"},{"author_name":"Ethel A. Garcia-Latorre","author_inst":"Escuela Nacional de Ciencias Biologicas, Instituto Politecnico Nacional, Mexico City, Mexico"},{"author_name":"Carmen M. Hernandez-Cardenas","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Shabaana A. Khader","author_inst":"Department of Molecular Microbiology, Washington University School of Medicine in St Louis, MO, United States"},{"author_name":"Albert Zlotnik","author_inst":"Department of Physiology & Biophysics School of Medicine, Institute for Immunology, University of California, Irvine, United-States"},{"author_name":"Joaquin Zuniga","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"}],"version":"1","license":"cc_no","type":"PUBLISHAHEADOFPRINT","category":"epidemiology"},{"rel_doi":"10.1101\/2020.08.11.20173203","rel_title":"A simple numerical and analytical analysis of Covid-19 progression, infection inhibition and control in various countries","rel_date":"2020-08-14","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.11.20173203","rel_abs":"Covid-19 disease outspread and its subsequent control and inhibition strategies in various countries have been different which led to quite drastic difference in the outcome of the disease progression. In this paper we present an analytical and numerical study of Covid-19 disease spread and control by applying the modified SIR model of epidemic outbreak to explain the Covid spread from February-July 2020 in various countries. Two approaches are evident from the disease progression; one focused on disease eradication and inhibition, and the other is less restrictive dynamic response. Both the approaches are analytically modeled to determine the parameters that characterize the effectiveness of dealing with the disease progression. The model successfully explains the Covid-19 evolution and control of various countries over a vast span of four-five months. The study is highly beneficial to simply analytically and numerically model this complex problem of epidemic proliferation. It assists to easily determine the mathematical parameters for the Covid-19 control measures, helps in predicting the end of the epidemic, and most importantly conceiving the judicious way of unlock process to restore communication between cities, states and countries.","rel_num_authors":3,"rel_authors":[{"author_name":"Uday Chakravarty","author_inst":"Raja Ramanna Centre for Advanced Technology, Indore"},{"author_name":"Deepa Chaturvedi","author_inst":"Department Applied Science, Alard College of Engineering and Management, Marunji, Pune"},{"author_name":"Mukesh P Joshi","author_inst":"Raja Ramanna Centre for Advanced Technology, Indore"},{"author_name":"Vinod Warrier","author_inst":"Southend University Hospital"},{"author_name":"Irina Duta","author_inst":"Southend University Hospital"},{"author_name":"Fiona Hayes","author_inst":"Southend University Hospital"},{"author_name":"Iman El Sayed","author_inst":"Alexandria University, EG"},{"author_name":"Yasser Noeman Ahmed","author_inst":"Southend University Hospital"},{"author_name":"David Goodman-Meza","author_inst":"UCLA Ronald Reagan"},{"author_name":"Anil Sapru","author_inst":"UCLA Ronald Reagan"},{"author_name":"Russell G Buhr","author_inst":"UCLA Ronald Reagan"},{"author_name":"Steven Y Chang","author_inst":"UCLA Ronald Reagan"},{"author_name":"Tisha Wang","author_inst":"UCLA Ronald Reagan"},{"author_name":"Nida Qadir","author_inst":"UCLA Ronald Reagan"},{"author_name":"Rachel Vreeman","author_inst":"Icahn School of Medicine at Mount Sinai"},{"author_name":"Joseph Masci","author_inst":"Icahn School of Medicine at Mount Sinai and New York City Health + Hospitals\/Elmhurst"},{"author_name":"Nick A Maskell","author_inst":"Academic Respiratory Unit, North Bristol NHS Trust, Bristol, UK"},{"author_name":"Shaney Barratt","author_inst":"Academic Respiratory Unit, North Bristol NHS Trust, Bristol, UK"},{"author_name":"Carlos Sanchez-Garibay","author_inst":"Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez (INNyN), Mexico City, Mexico"},{"author_name":"Gabriela Hernandez-Molina","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Criselda Mendoza-Milla","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Andrea Dominguez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Julio Granados","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Lula Mena-Hernandez","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Luis Angel Perez-Buenfil","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Guillermo Dominguez-Cheritt","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Carlos Cabello-Gutierrez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Cesar Luna-Rivero","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Jorge Salas-Hernandez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Patricio Santilla-Doherty","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Justino Regalado","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Angelica Hernandez-Martinez","author_inst":"Instituto Nacional de Medicina Genomica, Mexico City, Mexico"},{"author_name":"Lorena Orozco","author_inst":"Instituto Nacional de Medicina Genomica, Mexico City, Mexico"},{"author_name":"Ethel A. Garcia-Latorre","author_inst":"Escuela Nacional de Ciencias Biologicas, Instituto Politecnico Nacional, Mexico City, Mexico"},{"author_name":"Carmen M. Hernandez-Cardenas","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Shabaana A. Khader","author_inst":"Department of Molecular Microbiology, Washington University School of Medicine in St Louis, MO, United States"},{"author_name":"Albert Zlotnik","author_inst":"Department of Physiology & Biophysics School of Medicine, Institute for Immunology, University of California, Irvine, United-States"},{"author_name":"Joaquin Zuniga","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"}],"version":"1","license":"cc_no","type":"PUBLISHAHEADOFPRINT","category":"epidemiology"},{"rel_doi":"10.1101\/2020.08.10.20171819","rel_title":"Investigation of pooling strategies using clinical COVID-19 samples for more efficient diagnostic testing","rel_date":"2020-08-14","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.08.10.20171819","rel_abs":"When testing large numbers of clinical COVID-19 samples for diagnostic purposes, pooling samples together for processing can offer significant reductions in the materials, reagents, time, and labor needed. We have evaluated two different strategies for pooling independent nasopharyngeal swab samples prior to testing with an EUA-approved SARS-CoV-2 RT-qPCR diagnostic assay. First, in the Dilution Study, we assessed the assay's ability to detect a single positive clinical sample diluted in multiple negative samples before the viral RNA extraction stage. We observed that positive samples with Ct values at ~30 can be reliably detected in pools of up to 30 independent samples, and positive samples with Ct values at ~35 can be detected in pools of 5 samples. Second, in the Reloading Study, we assessed the efficacy of reloading QIAamp viral RNA extraction columns numerous times using a single positive sample and multiple negative samples. We determined that one RNA extraction column can be reloaded with up to 20 clinical samples (1 positive and 19 negatives) sequentially without any loss of signal in the diagnostic assay. Furthermore, we found there was no significant difference in assay readout whether the positive sample was loaded first or last in a series of 20 samples. These results demonstrate that different pooling strategies can lead to increased process efficiencies for COVID-19 clinical diagnostic testing.","rel_num_authors":5,"rel_authors":[{"author_name":"Samantha H Adikari","author_inst":"Los Alamos National Laboratory"},{"author_name":"Emily Z Alipio Lyon","author_inst":"Los Alamos National Laboratory"},{"author_name":"Attelia D Hollander","author_inst":"Los Alamos National Laboratory"},{"author_name":"Alina Deshpande","author_inst":"Los Alamos National Laboratory"},{"author_name":"Elizabeth Hong-Geller","author_inst":"Los Alamos National Laboratory"},{"author_name":"Fiona Hayes","author_inst":"Southend University Hospital"},{"author_name":"Iman El Sayed","author_inst":"Alexandria University, EG"},{"author_name":"Yasser Noeman Ahmed","author_inst":"Southend University Hospital"},{"author_name":"David Goodman-Meza","author_inst":"UCLA Ronald Reagan"},{"author_name":"Anil Sapru","author_inst":"UCLA Ronald Reagan"},{"author_name":"Russell G Buhr","author_inst":"UCLA Ronald Reagan"},{"author_name":"Steven Y Chang","author_inst":"UCLA Ronald Reagan"},{"author_name":"Tisha Wang","author_inst":"UCLA Ronald Reagan"},{"author_name":"Nida Qadir","author_inst":"UCLA Ronald Reagan"},{"author_name":"Rachel Vreeman","author_inst":"Icahn School of Medicine at Mount Sinai"},{"author_name":"Joseph Masci","author_inst":"Icahn School of Medicine at Mount Sinai and New York City Health + Hospitals\/Elmhurst"},{"author_name":"Nick A Maskell","author_inst":"Academic Respiratory Unit, North Bristol NHS Trust, Bristol, UK"},{"author_name":"Shaney Barratt","author_inst":"Academic Respiratory Unit, North Bristol NHS Trust, Bristol, UK"},{"author_name":"Carlos Sanchez-Garibay","author_inst":"Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez (INNyN), Mexico City, Mexico"},{"author_name":"Gabriela Hernandez-Molina","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Criselda Mendoza-Milla","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Andrea Dominguez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Julio Granados","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Lula Mena-Hernandez","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Luis Angel Perez-Buenfil","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Guillermo Dominguez-Cheritt","author_inst":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico"},{"author_name":"Carlos Cabello-Gutierrez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Cesar Luna-Rivero","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Jorge Salas-Hernandez","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Patricio Santilla-Doherty","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Justino Regalado","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Angelica Hernandez-Martinez","author_inst":"Instituto Nacional de Medicina Genomica, Mexico City, Mexico"},{"author_name":"Lorena Orozco","author_inst":"Instituto Nacional de Medicina Genomica, Mexico City, Mexico"},{"author_name":"Ethel A. Garcia-Latorre","author_inst":"Escuela Nacional de Ciencias Biologicas, Instituto Politecnico Nacional, Mexico City, Mexico"},{"author_name":"Carmen M. Hernandez-Cardenas","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"},{"author_name":"Shabaana A. Khader","author_inst":"Department of Molecular Microbiology, Washington University School of Medicine in St Louis, MO, United States"},{"author_name":"Albert Zlotnik","author_inst":"Department of Physiology & Biophysics School of Medicine, Institute for Immunology, University of California, Irvine, United-States"},{"author_name":"Joaquin Zuniga","author_inst":"Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER), Mexico City, Mexico"}],"version":"1","license":"cc_by","type":"PUBLISHAHEADOFPRINT","category":"public and global health"}]}



